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(Under the direction of Sally Stearns) 
Background: Over 900 Accountable Care Organizations (ACOs) have been created 
since 2010, and projections estimate that ACOs will manage the care for about one-third of 
Americans by 2025, however the impact of the MSSP on quality of care and patient outcomes is 
unclear.  
Objective: This study compared outcomes before and after MSSP implementation for 
patients who were either (1) discharged from hospitals that chose to participate (N=273) versus 
not participate(N=1,490) in MSSP or (2) assigned by Centers for Medicare & Medicaid Services 
(CMS) to a MSSP ACO versus not. I hypothesized that MSSP ACO participation would be 
associated with reduced inpatient utilization and improved outcomes of care.  
Methods: Using a difference-in-difference (DD) design, I evaluated outcomes associated 
with MSSP in a national inpatient stroke registry, Get With The Guidelines (GWTG)–Stroke, 
linked with Medicare claims for 2010–2015. Usage outcomes of discharge to home, number of 
hospital admissions, and Days Alive and Out of Hospital (DAOH) were modeled using negative 
binomial models with a log link and offset. Outcomes of all-cause rehospitalization, recurrent 
stroke, and all-cause mortality were modeled using Cox proportional hazards models. Outcomes 
of CMO or hospice enrollment within two weeks, hospice use within one year of hospitalization, 
hospice enrollment within seven days of death, and live discharge from hospice were modeled 
iv 
using logistic regression. Except for discharge destination, all outcomes were followed for up to 
one year following discharge, with appropriate adjustment for death.  
Key Findings: I found no evidence that hospital participation in the MSSP decreased 
inpatient use among stroke patients in the year following discharge, however beneficiary ACO 
alignment was associated with increases in subsequent admissions. Among patients most likely 
to benefit from palliative care, MSSP increased hospice enrollment and inpatient comfort 
measures without increasing rates of live discharge.  
Conclusion: Except for increased use of palliative care among stroke patients, current 
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This dissertation is organized in a non-traditional format. The first chapter provides a 
brief introduction to the topic and the specific aims of the dissertation. Chapter 2 includes the 
conceptual model and an overview of the approach taken in each study aim. Chapters 3, 4, and 5 
are manuscripts for the three study aims, intended to stand alone as publishable manuscripts and 
thus have redundancies with other chapters. Chapter 6 provides a summary of findings and 
policy implications and suggestions for future research. 
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CHAPTER 1. INTRODUCTION 
1.1 Background 
Since 2010, at least 900 Accountable Care Organizations (ACOs) have formed over 1,300 
payment contracts with public and commercial payers, and Medicare accounted for 563 of those 
contracts in 2017.
1-3
 The Centers for Medicare and Medicaid Services (CMS) implemented the 
Medicare Shared Savings Program (MSSP) to allow ACOs to retain a portion of the savings (or 
losses) generated by the coordination of care for Medicare fee-for-service (FFS) beneficiaries, 
within the FFS reimbursement structure. ACOs participating in MSSP generated Medicare 
savings of $429 million in 2015, largely through reductions in inpatient use.
4,5
 Although ACO 
quality scores have improved over time, it is unknown whether these metrics translate into 
improved health outcomes for patients.
6
 
Stroke treatment is an opportunity to improve the value of care due to the high cost as well 
as high mortality and morbidity rates among patients.
7
 Although stroke mortality declined over 
the past decade, it remains the fifth leading cause of death globally, and about 800K people in 
the United States experience stroke annually.
8
 Despite the high mortality rate, only about one-
third of ischemic stroke decedents receive palliative care services as recommended by American 
Heart Association guidelines.
9-12
 Although few MSSP quality metrics relate directly to the stroke 
population, the MSSP is expected to improve long-term health outcomes (e.g., reduce recurrent 
stroke and mortality) and reduce use of acute care services through health systems changes 
focused on discharge planning, care transitions, and care coordination, which may improve 
preventive therapies like medication persistence.
13-21





Stroke (GWTG–Stroke) has enrolled 1,600 hospitals in their program promoting adherence to 
acute-care guidelines. The registry provides a rich inventory of patient clinical factors and 
hospital quality of care to facilitate assessment of the impact of ACOs on stroke care. Linkage to 
Medicare claims in FFS beneficiaries allows for capture of post-discharge healthcare use and 
outcomes. 
The long-term goal of my research is to improve population health outcomes by 
informing payment strategies that will maximize value in health care. The goal of this study is to 
compare one-year outcomes for GWTG–Stroke patients assigned to an MSSP ACO or presenting 
at a hospital participating in an MSSP ACO to those meeting neither criterion over the 2010 to 
2015 period. The main hypothesis is that MSSP ACO participation is associated with improved 
clinical and patient centered outcomes. 
1.2 Study Purpose and Specific Aims 
Aim #1: Evaluate the association of MSSP with acute care use following incident stroke and 
sources of variation within ACOs. 
o Hypothesis: MSSP will be associated with reductions in rates of subsequent hospital 
admission and increases in discharge to home and days alive and out of hospital 
(DAOH) in the year after hospitalization for stroke.  
o Hypothesis: Among MSSP ACOs, ACO structural characteristics (e.g., year of entry, 
experience, primary-care focused, specialty-care focused, and size), market 
characteristics (e.g., poverty rate and population size) and MSSP market penetration 
(> 30% vs. ≤ 30% of hospital discharges aligned with any MSSP ACO), and ACO 
care continuity (beneficiary assigned vs. not assigned to the same MSSP ACO in 




Aim #2: Evaluate the association of MSSP with clinical outcomes following incident stroke. 
o Hypothesis: Among Medicare FFS beneficiaries, MSSP will be associated with 
reduced hazard rate for subsequent hospital admission, recurrent stroke, and all-cause 
mortality within one year relative to non-MSSP. 
Aim #3: Evaluate the association of MSSP with quality of care at the end of life. 
o Hypothesis: MSSP will be associated with improved quality of care at the end of life 
measured by 1) increased hospice use among those with high mortality risk at 
discharge and 2) increased length of hospice use among hospice users in all care 
settings (e.g., stay less than 7 days, live discharge, and median days in hospice). 
Given the rapid adoption of the ACO strategy nationally, it is essential that we 
understand the relationship between ACOs and health outcomes to improve the implementation 
of the ACO strategy. This is a novel analysis of the potential impacts of ACOs for stroke 
patients. These results will inform the direction of the Medicare ACO program and determine 
whether the current quality metrics and savings eligibility requirements are sufficient for 
impacting stroke outcomes.  
1.3 Study Significance 
The proposed research is significant because it evaluates the impact of a novel payment 
strategy on health outcomes and quality of care in the context of a costly disease with high rates 
of mortality and morbidity. Stroke is the fifth leading cause of death in the United States and is 
responsible for 17.2 billion in medical expenditures annually.
8,22
 ACOs aim to achieve the triple 
aim of better outcomes and patient experience with lower costs, however it is unknown whether 
the MSSP quality metrics translate into improved health outcomes for stroke patients.
6
 Despite 
the high mortality rate among stroke patients, services associated with high-quality end-of-life 
care, hospice, and palliative care are underused among stroke patients.
12,23
 This study will 
 
4 
improve our understanding of how MSSP ACOs are impacting use, outcomes, and quality of 
end-of-life care following stroke.  
1.4 Research Question and Hypotheses  
The goal of this study is to compare one-year outcomes among two populations: 1) 
GWTG–Stroke patients assigned to an MSSP ACO or presenting at a hospital participating in an 
MSSP ACO, and 2) GWTG–Stroke patients with neither exposure over the period 2010 to 2015. 
My overall hypothesis was that MSSP participation would shift care to less intensive care 
settings following stroke without adversely impacting clinical outcomes. I tested these 
hypotheses using the following three aims: 
Aim #1: Evaluate the association of MSSP with acute care use following incident stroke 
and sources of variation within ACOs. 
Aim #2: Evaluate the association of MSSP with clinical outcomes following incident 
stroke. 
Aim #3: Evaluate the association of MSSP with quality of care at the end of life. 
Specifically, I hypothesized that MSSP will be associated with reduced acute health 
services use without negatively impacting clinical outcomes as well as improved quality of care 
at the end of life among patients meeting criteria for Limited Life Expectancy (LLE). 
1.5 Conceptual Model  
From 2003 to 2013, stroke deaths declined by 18% due in part to advances in stroke 
treatment as well as improved use of pharmacotherapy for primary and secondary prevention; 
however, 800,000 people in the United States are hospitalized for stroke each year with a one-
year mortality rate over 30%.
8
 The risk of stroke increases with age, and two-thirds of strokes 
occur in those age 65 or older.
8
 Health services use remains high over the year following 
hospitalization for stroke, and post-acute care (PAC) is typically provided in skilled nursing 
 
5 
facilities (SNFs), inpatient rehabilitation facilities (IRFs), home health (HH) agencies, and/or 
outpatient (OP) rehabilitation settings.
24
  
Medicare ACO models including Pioneer and MSSP have been marginally successful in 
reducing costs, primarily through reductions in acute care services, though performance is highly 
variable among ACOs.
5,25-31
 Predecessors to the MSSP demonstrated moderate success in 
reducing acute care use (inpatient use, emergency department use, and readmission rates) as well 
as post-acute services (skilled nursing facilities and home health visits).
4
 ACOs are expected to 
prevent hospital admissions and readmissions through preventive services (e.g., medication and 
lifestyle changes) and coordinated outpatient care.  
ACOs are intended to achieve the triple aim of better outcomes and patient experience 
with lower costs, however it is unknown whether the MSSP quality metrics translate into 
improved health outcomes for patients.
6
 Patients with stroke could potentially benefit from these 
care pathways due to the high risk of adverse outcomes (e.g., recurrent stroke and mortality).
32
 
Early ACOs were effective in reducing acute care service use among groups with cardiovascular 
disease, at high risk for hospitalization, and with prior hospitalization.
33
 Reductions in acute care 
use may be due in part to improvements in care transitions, with greater use of physician visit 
within seven days of discharge from the hospital.
4
 Prior studies have not found an association 
between ACO status and short-term outcomes (30-day mortality, in-hospital complications, 
readmissions, or inpatient length of stay) among hospitalized patients (cancer surgery or 
traumatic injury),
26,34
 but the impact on longer term health outcomes is unclear.  
Palliative care services, including use of the Medicare hospice benefit, have the potential 
to improve the quality of end-of-life care, yet these services are underused among stroke 
patients.
12,23
 The American Heart Association recommends that all stroke patients should receive 
 
6 
palliative care early in the disease trajectory; however, only about one-third of ischemic stroke 
decedents receive this evidence-based service. 
9-12
 Palliative care is patient- and family-centered 
care that optimizes health-related quality of life by anticipating, preventing, and treating 
suffering. Use of palliative care via Medicare hospice benefit improves the quality of end-of-life 
care; however, these benefits may not be realized for the 1 in 3 hospice beneficiaries with 




Figure 1. Causal pathways for the impact of the Medicare Shared Savings Program on outcomes 
for stroke patients. 
 
 
Among stroke patients, ACOs are hypothesized to impact one-year health outcomes 
through improved care coordination, chronic disease management, non-medical social supports, 
and population management processes (Figure 1).
13-20,42
 For example, patient-centered medical 
homes, one strategy used by ACOs to manage populations with multiple chronic comorbidities, 
is positively associated with initiation of oral anticoagulation therapies among patients with atrial 
fibrillation.
43
 Among Medicare stroke patients, 30-day readmission rates range from 15% to 
39%, with higher rates among patients with multiple chronic conditions. Furthermore, at least 
 
7 
10% of these readmissions were potentially preventable.
24,33,44
 Hospital quality improvements 
(e.g., prescription of evidence-based medications at discharge and better care transitions at 
discharge) are expected to impact outcomes for all patients, regardless of whether the beneficiary 
is ACO-aligned. 
MSSP has the potential to enhance the quality and value of end of life care by increasing 
use of palliative care, including hospice, as well as reducing stroke recurrence and mortality 
through care coordination. As in other alternative payment models, ACOs are expected to use 
palliative care, including hospice, as a strategy to improve symptom control and patient 
satisfaction, while reducing hospitalizations and ensuring value in services used.
45-52
 Prior 
research has found ACOs are associated with decreased days in hospice in the general Medicare 
population.
4,5,27
 This decrease could be driven by reductions in the proportion of stays longer 
than 180 days with the goal of reducing costs and improving appropriate use of the hospice 
benefit. If this is the case, it is possible to find a decrease in the average hospice days per capita 
and at the same time an increase in proportion of people using hospice at death and the median 
hospice stay. Other measures of appropriate hospice use such as the timing of hospice use 
relative to death have not been evaluated. This proposed study will extend the evaluation of 
MSSP ACOs to include impacts on long term health outcomes in a post-acute setting as well as 









CHAPTER 2. APPROACH 
2.1 Overview and Rationale 
The goal of this study is to compare one year outcomes among two populations: 1) 
GWTG–Stroke patients assigned to an MSSP ACO or presenting at a hospital participating in an 
MSSP ACO, and 2) GWTG–Stroke patients with neither exposure over the period 2010 to 2014. 
To achieve this objective, the study used hospitalization data from a national registry linked to 
Medicare FFS claims data in an observational study design. Hospitals choosing to participate in 
the MSSP are likely to be different from those that do not participate in ways that are correlated 
with the outcomes of interest. To control for this selection bias, each of the three aims used a 
difference-in-difference analysis to control for the differences between the MSSP hospitals and 
non-MSSP hospitals that remain fixed over the study period.  
My overall hypothesis was that MSSP incentives for cost reduction would shift care to 
less intensive care settings following stroke without adversely impacting clinical outcomes. To 
determine the association of MSSP with acute care use, Aim 1 employed negative binomial 
models with a log link and offset to measure rates of discharge to home, hospital admission, and 
Days Alive and Out of the Hospital in the year following incident stroke. To determine the 
association of MSSP with clinical outcomes, Aim 2 used cox proportional hazards models with 
dependent variables of rehospitalization, recurrent stroke, and mortality in the year following 
incident stroke. To determine the association of MSSP with hospice use among patients with 
Limited Life Expectancy (LLE), Aim 3 used logistic regression models with outcomes of any 
hospice use within one year of incident stroke, comfort measures only within 2 weeks of 
 
9 
discharge, short stay in hospice (<7 days), and live discharge from hospice among hospice users. 
In addition, quantile regressions were used to evaluate shifts in the distribution of hospice days 
by MSSP status. 
2.2 Innovation 
This study will use both hospital- and beneficiary-level measures of MSSP exposure to 
improve the precision of the estimated effect. Specifically, MSSP hospitals are defined as 
hospitals participating in an ACO with an MSSP contract, and ACO-aligned beneficiaries are 
defined as beneficiaries assigned to an MSSP ACO using CMS claims-based algorithms.
53
 
Beneficiaries discharged from a hospital participating in MSSP may not be assigned to any 
MSSP ACO. In the evaluation of the effect of MSSP hospitals, the treated group includes 
patients receiving acute stroke care for incident stroke at an MSSP hospital, including patients 
not assigned to any ACO. In the evaluation of beneficiary alignment, the treated group includes 
beneficiaries assigned to any MSSP ACO in CMS MSSP beneficiary-level files, which identify 
beneficiaries who receive a plurality of their primary care from ACO providers based on 
allowable charges regardless of whether acute stroke care was received at an MSSP hospital.
1
  
Thus, MSSP hospitals are expected to impact care for all patients regardless of 
beneficiary ACO alignment through inpatient care processes and discharge planning. However, 
models evaluating MSSP hospitals that do not also control for beneficiary ACO alignment may 
be biased through contamination of the control group if the patients who present at a control 
hospital are assigned to an ACO. As a result, estimate for MSSP hospitals may be biased toward 
the null and understate the association with outcomes. Likewise, failing to account for the MSSP 
                                                 
1
 In the patient-level definition for the MSSP program, CMS identifies beneficiaries who received at least one 
primary care service from a physician who is a member of an ACO and then employs a step-wise process to 
determine ACO assignment with the goal of attributing beneficiaries to an ACO if more care was received from that 
ACO (defined by allowed charges) than any other ACO or non-ACO providers. (42 CFR 425.402 - Basic 
assignment methodology.)   
 
10 
hospital effect on non-ACO patients during the inpatient stay could also result in attenuation bias 
for the estimated effect of beneficiary ACO-alignment. Up to 90% of beneficiaries receive care 
outside of the ACO, and 25% to 30% of ACO-aligned beneficiaries change from year to 
year.
5,33,54,55
 Thus, this study improves on current evidence by accounting for both the hospital-
level assignment and the patient-level assignment reducing misclassification and improving 
precision in estimating the effect of MSSP.  
Second, existing studies of MSSP using claims data have limited controls for case mix 
and severity, which are critical adjustment factors for assessing variation in outcomes. The 
GWTG registry provides a rich set of clinical covariates and demographic data to reduce bias 
from unmeasured case mix variation that may occur in claims-only analyses. Among the key 
clinical covariates captured in GWTG–Stroke is severity of stroke on neurologic exam, one of 
the most important factors in predicting short- and long-term outcomes after discharge.
56
 
Furthermore, risk adjustment reduces bias in the evaluation of ACO characteristics associated 
with high impact on outcomes by controlling for case mix variation across ACO types. 
Finally, I evaluated the use of comfort measures only (CMO) for a subgroup of patients 
prospectively identified during hospitalization by physicians and predictive measures as having 
Limited Life Expectancy. Studies of end-of-life care frequently retrospectively identify the 
population in need of palliative care using date of death, however in practice physicians can only 
be held accountable for improving the quality of end-of-life care for patients who can be 
identified prospectively. Using these novel data, this project will generate new knowledge about 




2.3 Data Sources 
Hospitalization records from the GWTG registry for the study period (2010–2014) were 
linked to CMS denominator, MSSP, and inpatient and hospice claims files (2010–2015) using a 
validated algorithm (Hammill, 2009).
57
 The GWTG–Stroke Program was developed by the 
American Heart Association/American Stroke Association (AHA/ASA) as a national stroke 
registry and performance improvement program. The primary goal was to improve the quality of 
care and outcomes for stroke and transient ischemic attacks by promoting consistent adherence 
to the latest scientific treatment guidelines. This national registry, which includes 5 million 
discharges since 2003 at 1,656 hospitals, is similar in clinical characteristics to the larger 
Medicare FFS population.
58
 This high-quality data source has an average 90% retention of 
hospitals sites and over 96% reliability of measures.
59,60
  
Participating hospitals submit hospitalization-level data on patient risk factors, diagnostic 
testing results, in-hospital and discharge treatments, adherence to acute and discharge 
performance measures, defect-free care measures (e.g., information on how well hospitals 
provided appropriate care for all patients), composite care measures (e.g., overall measures that 
reflect total care of patients), and in-hospital outcomes. In addition, hospital characteristics 
including ownership, stroke center status, teaching hospital status, number of beds, rural status, 
and Census region are available.  
2.4 Sample Size and Power 
Sample Identification 
The sample included Medicare FFS patients hospitalized in a hospital participating in the 
GWTG–Stroke registry between January 2010 and December 2014 who are age 65 or older with 
a final diagnosis of ischemic stroke and linked to CMS claims. Exclusion criteria include prior 
stroke, admission year greater than discharge year, missing all prior medical history, or 
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registered at sites missing more than 25% of baseline data. To obtain longitudinal outcomes, we 
used a previously validated probabilistic matching technique to link in-hospital data from 
GWTG–Stroke to Medicare claims data.
57
  
Linkage to CMS files used FFS claims and thus was only possible for Medicare FFS 
beneficiaries. To better understand the generalizability of findings to Medicare Advantage (MA) 
beneficiaries and FFS beneficiaries that did not link, I compared demographics, medical history, 
and clinical factors of eligible Medicare hospitalizations in the GWTG registry who successfully 
linked to CMS claims (N=352,318) with those 65 years and older but unable to link (N=222,818) 
(e.g., Medicare Advantage hospitalizations and Medicare FFS hospitalizations that failed to link 
with CMS) in Table 1. Standardized difference scores are used to compare baseline covariates 
between CMS linked and unlinked discharges. Unlike a t-test or Wilcoxon rank-sum test, 
standardized differences are independent of sample size because they express the average 
difference between means in standard deviation units.
61
 Hospitalizations that fail to link are 
primarily Medicare Advantage patients that have no FFS claims to support the linkage process, 
however I am unable to identify FFS from Medicare Advantage (MA) patients in the absence of 
linkage to CMS files.  
In this sample, FFS-linked patients were older with an average age of 80 compared to 78 
among those that failed to link, which is consistent with national comparisons of Medicare 
Advantage and FFS patients (Table 1).
62
 Other patient demographics, medical history, clinical 
measures, and hospital factors were not substantially different (standardized difference <0.2) 
between the two groups except for location in the West Census region (standardized difference 
=0.24). After excluding duplicates and patients not FFS at discharge (N= 24,124), my analytic 
cohort included 328,194 beneficiaries (Figure 2). 
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Table 1. Characteristics of Eligible Get With The Guidelines–Stroke Registry Discharges by 
Fee-For-Service Medicare Linkage Status (2010–2014) 
 
N= 352,318       N= 222,818       
Variable Mean SD Mean SD StDif
Patient Characteristics
Registry Patient Age median (25th-75th percentile) 80.0 (73-86) 78.0 (71-85) 0.19
Female 57.7% 54.3% 0.07
medicaid 7.1% 8.0% 0.05
private 38.0% 41.5% 0.01
Black 9.7% 13.3% 0.04
Hispanic 3.8% 8.2% 0.02
Hospitalization Characteristics
Discharge to Home 39.2% 45.0% 0.12
Discharge to Skilled Nursing Facility 4.0% 3.3% 0.12
Discharge to Home Health 1.7% 1.6% 0.12
Discharge to Inpatient Rehabilitation Facility 4.4% 3.0% 0.12
Discharge to Hospice 6.2% 5.3% 0.00
Inpatient Death 5.5% 5.6% 0.04
Length of Stay 5.0 (4.6) 5.3 (5.9) 0.16
Mortality Risk Factors
NIH Stroke Severity on Admission 7.4 (8.4) 7.0 (7.9) 0.05
CHA2DS2-VASc Score [D] 4.1 (1.9) 3.9 (1.3) 0.04
Historic: Modified Rankin Scale at Discharge 4.4 (0.8) 4.3 (1.9) 0.04
What was patient’s ambulatory status at discharge? 2.7 (8.6) 2.7 (0.8) 0.09
GWTG Global Stroke Estimated Mortality Rate (Ischemic Stroke, SAH, ICH, Stroke not otherwise specified)6.4 (8.5) 5.7 (7.9) 0.08
Medical History
Medical History - Prosthetic heart valve 1.6% 1.4% 0.08
Medical History - CAD/prior MI 30.5% 27.8% 0.02
Medical History - Carotid Stenosis 4.0% 3.7% 0.06
Medical History - Diabetes Mellitus 31.6% 34.0% 0.02
Medical History - PVD 5.4% 5.0% 0.05
Medical History - Hypertension 83.8% 84.2% 0.02
Medical History - Smoker 10.0% 12.2% 0.01
Medical History - Dyslipidemia 48.8% 49.2% 0.07
Medical History - HF 11.5% 10.0% 0.01
Medical History - Drugs/Alcohol Abuse 0.5% 2.6% 0.03
Medical History - Family History of Stroke 3.0% 3.1% 0.03
Medical History - HRT 0.2% 0.2% 0.16
Medical History - Migraine 0.5% 0.6% 0.00
Medical History - Obesity/Overweight 5.8% 7.0% 0.00
Medical History - Renal insufficiency - chronic (SCr>2.0) 3.7% 4.2% 0.01
Medical History - Sleep Apnea 0.5% 0.6% 0.05
Medical History - Depression 1.7% 2.0% 0.02
FFS Linked *
Medicare Advantage or 







Limited Life Expectancy Subgroup 
Patients with stroke have varied care trajectories depending on the severity of stroke, 
preferences, and health status. Many strokes are mild or moderate and post-stroke care is focused 
on rehabilitation and preventive measures. Patients with severe stroke or poor health status may 
have different goals for their care, particularly if they have limited life expectancy. For this 
study, beneficiaries meeting any one of the following criteria were identified as Limited Life 
Expectancy (LLE).  
 National Institutes of Health Stroke Scale (NIHSS) score of ≥15, which indicates a 
high probability of death or severe disability
56
 
Variable Mean SD Mean SD StDif
Inpatient Clinical Measures
Measurements: BMI 27.2 (6.8) 27.5 (6.8) 0.04
Measurements: Diastolic BP at Discharge 71.4 (12.4) 71.8 (12.4) 0.04
Measurements: Systolic BP at Discharge 137.7 (21.3) 137.3 (20.9) 0.02
Measurements: A1C (0-20), % 6.5 (1.5) 6.6 (1.6) 0.05
Measurements: Lipids - HDL (0-120), mg/dL 45.4 (14.6) 45.2 (14.5) 0.01
Measurements: Lipids - LDL (30-500), mg/dL 96.3 (37.5) 97.3 (37.7) 0.03
Measurements: Vital Signs - Heart Rate (30-200), bpm 79.9 (18.1) 79.9 (18.2) 0.00
Measurements: INR (International normalized ratio) (0-25) 1.2 (0.6) 1.2 (0.6) 0.03
Measurements: Serum Creatinine (0-150), mg/dL 1.4 (4.9) 1.4 (4.6) 0.00
Dysphagia screening result 1.3 (0.5) 1.3 (0.5) 0.05
Hospital Characteristics
SiteTrait: Rural Location [D] 5.6% 4% 10%
SiteTrait: Teaching Hospitals [D] 57.2% 59.5% 0.05
SiteTrait: Primary Stroke Center 100% 100.0% 0.00
SiteTrait: # of Beds in Hospital [D] 415.9 430.1 0.05
Northeast 26.0% 28.6% 0.06
Midwest 21.5% 16.6% 0.13
South 36.9% 29.5% 0.16
West 15.6% 25.3% 0.24
*Includes 24,124 observations that were not FFS at discharge but were FFS at some time during the year.
FFS Linked *
Medicare Advantage or 
failed to link to FFS
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 GWTG mortality risk (global or ischemic) prediction score > 0.15 
 Contraindication for evidence based treatment due to provider reported limited life 
expectancy (GS_Reasonnoantithrom_8, GS_rehabsvcs_5, GS_relexclusion_3, 
GS_whynoatrialmeds_5, GS_NOIVWARNING2_8) 
Additional LLE for Aims 1 and 2: 
 Discharge to hospice (GWTG registry dispositioni).  
 Registry reported comfort measures only received at any point during the index 
hospitalization. (GS_Comfort Only < 4) 
The effect of MSSP is evaluated separately among the group meeting LLE criteria (20% 
of the linked cohort) and the other patients due to the substantial differences baseline hazards and 
care trajectories. Although these criteria are not validated or published prior is identified as LLE 
and the one-year mortality rate for the subgroup meeting at least one LLE criteria is 63% versus 
18% in the rest of the sample.  
Sample 1: Aims 1-2 
Beneficiaries who linked to CMS FFS claims but were not FFS at the time of discharge 
were excluded (N=24,124). Other exclusions were patients who died during the index 
hospitalization (n=19,742), discharge disposition as Left Against Medical Advice (n=838), or 
missing Area Health Resource File (AHRF), race, or discharge disposition (n=1,881). Finally, 
patients meeting the criteria for LLE were excluded (N=54,128) because the care trajectories are 
expected to be much different in this subgroup than in the rest of the sample, resulting in a final 
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Sample 2: Aim 3 
Beneficiaries who linked to CMS claims but were not FFS at the time of discharge were 
excluded (N=24,124). Other exclusions included discharge disposition as Left Against Medical 
Advice (n=838), or missing AHRF, race, or discharge disposition (n=1,881). Finally, patients 
with index hospitalization in 2014 (n=68,793) were not included because one full year of follow-
up in hospice claims was not available. Of 256,682 patients in the final sample, 56,483 were 
identified as Limited Life Expectancy (LLE) (Figure 3). Models included an interaction with the 
LLE indicator to test for effect heterogeneity within this subgroup.  
Power 
Power to detect differences in mortality is based on the following assumptions. 
Discharges from hospitals participating in MSSP (treated group) was expected to be 20% of the 
sample (actual proportion in analysis cohort was 19.2%), which is higher than the ACO 
distribution in the general population at that time because hospitals participating in GWTG are 
more likely to be located in urban areas where ACOs are more prevalent than the general 
population of hospitals. In the year following incident stroke, the baseline mortality rate was 
estimated to be at least 25% (actual mortality rate in analysis cohort was 29%),
63
 and based on 
studies of similar payment programs, I expected a potential reduction in mortality rates of 1 
percentage point 
64,65
 resulting in a hazard ratio between 0.96 and 0.97. Given a sample of at least 
100,000 patients (actual analysis sample for the clinical outcomes is 251,605), this analysis had 
>80% power to detect a hazard ratio of at least 0.97 (Figure 4). The baseline rate of 
rehospitalization is over 0.60 and we expect a potential reduction of 5 to 10 percentage points; 
there is sufficient power given this sample size to detect the expected hazard ratio of 0.83–0.91. 
However, this analysis is not powered to detect a hazard ratio of lesser magnitude; this analysis 
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would have reduced power to detect the same hazard ratio for recurrent stroke, which has a one-




Figure 4. Power by hazard ratio for mortality. 
 
 
2.5 Selection Bias 
CMS MSSP Assignment Methodology 
CMS uses a claims-based algorithm to assign beneficiaries to the ACO or non-ACO 
provider group providing the plurality of primary care, as defined by allowed charges. To be 
eligible for assignment to an ACO, beneficiaries must have at least one month of Part A and Part 
B enrollment and one evaluation and management claim delivered by a practitioner (identified 
by National Provider Identifier) participating in an ACO with an MSSP contract, including 
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Centers. A beneficiary is assigned to an ACO if the allowed charges for primary care services 
given to the beneficiary by primary care practitioners at the participating ACO are greater than 
the allowed charges for primary care services furnished by primary care practitioners in any 
other ACO and greater than the allowed charges for primary care services from the same types of 
providers in each non-ACO individual or group tax id number or CMS certification number. 
In the MSSP beneficiary level files, CMS provides two types of assignment indicators 
using the same algorithm over different claims periods. The final assignment flag is based on an 
annual application of the algorithm using claims for services provided during the performance 
year with a 90-day run out to capture claims submitted up to 90 days following the end of the 
year. The preliminary assignment flag is based on quarterly application of the algorithm using 
claims for services provided over a rolling 365 day period (Figure 5). 
 
 
Figure 5. Illustration of the claims period used for the CMS preliminary Quarterly assignment of 





MSSP Immortal Time Bias  
Like other claims-based algorithms, the MSSP assignment methodology relies on the 
accumulation of claims over time to increase sensitivity of the identification. As the time at risk 
increases, the prevalence of the MSSP assignment in the sample increases. This creates the 
potential for selection bias in the program related to time at risk, including survival time. As a 
result, the time period used in the assignment algorithm must be prior to the index date or start of 
follow-up to avoid immortal time bias. 
Using the final assignment flag for the year of index hospitalization to identify MSSP 
beneficiaries would selectively exclude patients with short survival periods following stroke 
from the treatment group. In this scenario, at least part of the claims period used to identify 
MSSP beneficiaries would occur after the index date, causing patients who live longer following 
stroke have greater probability of being assigned to the treatment group. Those who do not 
survive long enough to be assigned default to the control group, resulting in biased estimates for 
the association between MSSP and outcomes correlated with survival.  
Using the preliminary quarterly assignment flag in the quarter of index hospitalization to 
identify MSSP beneficiaries mitigates the bias for beneficiaries who survive at least 90 days 
following stroke because at least three quarters of the period used to identify MSSP would occur 
prior to the index date (Figure 6). To completely prevent the potential for this source of bias, the 
quarterly assignment flag for the quarter prior to discharge was used to identify MSSP 
beneficiaries. This ensures all beneficiaries survived to the end of the period used to identify the 
treatment group. Because the MSSP assignments is based on usage patterns over the year prior to 
the quarter of hospitalization, there is no guarantee that those patients identified as MSSP 
continue to use MSSP providers for their primary care during the follow-up period. Thus, this 
treatment definition is similar conceptually to an “intent to treat” analysis in which “treated” 
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patients adherence to and completion of the assigned treatment is not assured. I expect this 




Figure 6. Odds ratios illustrating the association between beneficiary survival following stroke 
and assignment to the MSSP by 1) Retrospective Performance Year (PY) and 2) Prospective 
Quarterly (QTR) Assignment during quarter of discharge.  
 
 
2.6 Key Variables and Measures 
Exposures 
ACO status for hospitals and beneficiaries was obtained from the CMS MSSP provider-
and beneficiary-level files for performance years 2013 and 2014. For this analysis, I defined 
MSSP exposure using 1) hospital- or provider-level participation in MSSP and 2) CMS 
beneficiary assignment to MSSP. First, the hospital MSSP indicator is 1 when the patient is 
discharged from a hospital participating in an MSSP in any year during the study period as 
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determined by the CMS MSSP ACO provider-level files (MSSP performance years 2013 and 
2014), and the hospital MSSP indicator is 0 for discharges at hospitals not participating in MSSP 
in any year during the study period; the time indicator for post-hospital MSSP implementation is 
1 when the date of discharge is after the date of the hospital initiation of the MSSP contract (e.g., 
April 1, 2012; July 1, 2012; or January 1, 2013, for performance year 2013 and January 1, 2014, 
for performance year 2014) and before the most recent end date for the hospital participation in 
MSSP; otherwise the indicator for post implementation is 0.  
Second, the indicator for ACO-aligned beneficiaries equals 1 when the CMS MSSP 
beneficiary-level files identified the patient as assigned to any MSSP ACO in the quarter prior to 
discharge using the preliminary quarterly assignment algorithm and 0 otherwise.
55
  
These two types of exposure result in three treatment arms. The control group consists of 
1) beneficiaries not assigned to an MSSP ACO in the quarter prior to discharge and 2) admitted 
to a hospital not participating in MSSP at the time of discharge. The effect of hospital 
participation in MSSP will be assessed among beneficiaries not assigned to MSSP but 
discharged from a hospital participating in MSSP at the time of discharge. Finally, the effect of 
beneficiary assignment to MSSP will be assessed among ACO-aligned beneficiaries controlling 
for hospital participation in MSSP.  
Hospital  
Each difference-in-difference analysis had two key variables (MSSP exposure and time 
period) whose interaction identifies the differential change in the MSSP treatment group in that 
time period relative to the baseline period. First, each hospital admission record was assigned to 
one of four time periods by discharge date, two time periods prior to the hospital’s MSSP 
contract initiation date and two time periods post initiation (Figure 7).
32
 MSSP contracts were 
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initiated in April 1, 2012; July 1, 2012; October 1, 2012, or January 1, 2013, for performance 
year one (PY) one or January 1, 2014, for PY2. Discharges prior to MSSP initiation were 
assigned to either the baseline period (more than 6 months prior to hospital MSSP initiation) or 
the run-up periods (within 6 months of hospital MSSP initiation). Post-MSSP discharges were 
assigned to either early MSSP (within 6 months of hospital MSSP initiation) or sustained MSSP 
(greater than 6 months after hospital MSSP initiation). The run-up period was intended to 
remove from the baseline referent period any impact from ACOs implementing care coordination 
process improvements and other quality improvement measures in anticipation of the official 
ACO start date. Furthermore, care coordination and other process improvements may take 
months to implement, so the greatest effects are expected for admissions occurring 6 months 
after initiation when the health systems have more fully implemented their quality 
improvements. However, models failed to detect a significant differential change for the MSSP 
group during the run up period, so the run up period was collapsed into the baseline period. Prior 
studies found decreases in total spending similar in magnitude in the first 6 months and first 
year.
32
 Similarly, the two post periods were also collapsed for the main models presented due to 
lack of significantly different effects, however the differential impact of years of experience was 








Aim 1: Measures of acute care use in the year following discharge were 1) discharge to 
home, 2) Days Alive and Out of Hospital (DAOH), and 3) number of all-cause hospital 
admissions. Discharge to home was defined using the registry discharge disposition status. 
Patients not discharged to home were primarily discharged to inpatient rehabilitation facilities 
(IRF) or skilled nursing facilities (SNF) or other acute care facility (<5%). DAOH and number of 
hospital admissions were defined using Medicare inpatient claims and denominator files. Days 
alive and out of hospital was counted starting at hospital discharge for 365 days. DAOH is 
calculated as the number of days alive and on FFS (DALIVE) and spent outside of a hospital 
(DHOSP), or an inpatient rehabilitation facility (DREHAB). For any patient i, then: 
HTi = DALIVE, i – DHOSP, i– DREHAB, i 
All use outcomes are conceptualized as a count per days of follow-up (or in the case of 
discharge to home count per discharge). Days of follow-up are censored at the first non-FFS day 
after discharge, one year of follow-up, death, or end of study period. The study end date was 
December 31, 2015, for all outcomes except recurrent stroke. The study end date for stroke was 
October 1, 2015, because of the transition to the International Classification of Diseases, Tenth 
Revision (ICD-10) and the lack of validation and comparison of the sensitivity and specificity of 
the definition of recurrent stroke in ICD-9 and ICD-10. In addition, inpatient days were not 
included in the days at risk for hospitalization so the offset for number of admissions was the log 
of DAOH. 
Aim 2: Clinical outcomes in the year following discharge include 1) all-cause 
rehospitalization, 2) recurrent stroke, and 3) all-cause mortality. All-cause rehospitalization and 
recurrent stroke were defined using the Medicare inpatient claims files. A recurrent stroke was 
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identified by a principal diagnosis including ICD-9 codes 430 to 434 or 436 to 437 for a 
hospitalization or observation stay in the follow-up period.
66
 Date of death was provided by the 
CMS beneficiary summary file. All-cause mortality was measured rather than stroke-specific 
because a high proportion of deaths (44%) following stroke are due to non-stroke causes.
67
 In 
addition, ACOs are expected to impact mortality from all causes by coordinating care for 
patients with competing risks of death due to multiple comorbidities. Finally, the difficulty of 
ascertaining cause of death with high validity supported the use of all-cause mortality. All use 
outcomes were conceptualized as a count per days of follow-up (or in the case of discharge to 
home count per discharge). For mortality, days of follow-up were censored after one year of 
follow-up, death, or end of study period. For use outcomes defined by inpatient claims 
(rehospitalization and recurrent stroke), days of follow-up are censored at the first non-FFS day 
after discharge, death, 365 days after discharge, or end of study period. Although claims were 
available through December 31, 2015, the end of the study period was defined as October 1, 
2015, for the outcome of recurrent stroke because of the transition to ICD-10 and the lack of 
validation and comparison of the sensitivity and specificity of the definition of recurrent stroke in 
ICD-9 and ICD-10.  
Aim 3: Though there is no consensus about measures to define quality of care at the 
end of life, palliative care and hospice care have been associated with quality of care at the 
end of life.
35-39
 Measures of quality of end-of-life care included use of comfort measures 
only or hospice as well as the timing of hospice enrollment among hospice users. Although 
the importance of palliative care concurrent with curative care is recognized, claims 





To capture outcomes more proximate to the hospitalization and expected to be 
impacted by hospital participation in MSSP, a binary composite outcome was defined as 1 
when a patient received comfort measures only during the index hospitalization or enrolled 
in hospice within 2 weeks of discharge and 0 otherwise. To capture long-term outcomes 
expected to be impacted by the beneficiary assignment to MSSP, a binary outcome 
indicating hospice use within one year of admission was defined. Among hospice users, 
measures for the timing of hospice enrollment included enrollment within 7 days of death 
(binary), which is associated with the patient/family perception of being enrolled too late, 
and live discharge from hospice (binary), which has been used as a proxy for early 
enrollment, as well as total number of days in hospice (continuous). 
 
 
Table 2. Summary Table 
 
Outcome  Specification Time from Discharge Model
AIM 1 Exclusions:
Clinical Outcomes (N=251,605 )
Time to All-Cause Rehospitalization Binary, Days follow up 1 year
Time to Recurrent Stroke Binary, Days follow up 1 year
Time to All Cause Mortality Binary, Days follow up 1  year
Acute Care Utilization (N= 251,605)
Discharge to Home Count (0-1) Discharge
Number of Hospital Admissions Count (0-N) 1 year
Days Alive and Out of Hospital Count (0-365) 1 year
AIM 2 Exclusions:
Quality of End of life Care (N= 256,682)
Composite Comfort Care Binary  2 weeks
Hospice Use Binary  1 year
Subgroup 1:
Quality of End of life Care 
Days in Hospice (N= 72,115) Continuous Hospice duration 
Quantile Regressions at 
25/50/75 percentiles and GLM
Live Discharge from Hospice (N= 72,115) Binary Hospice duration Logistic Regression
Subgroup 2:
Short Stay <7 days (n=63,956) Binary Hospice duration Logistic Regression
Inpatient Death (n=19,742) Left Against Medical Advice (n=838) Missing 
AHRF, Race or Discharge (n=1,881); Life Expectancy  where LLE=discharge to 
hospice, comfort measures only, NIHSS>15, or GWTG Mortality Risk 
2014 Hospitalizations Excluded (68,793) Left Against Medical Advice (n=838) 
Missing AHRF, Race or Discharge (n=1,881)
Beneficiaries with any Hospice claim within 2 years of Discharge
Beneficiaries with any Hospice claim within 2 years of Discharge and 
surviving at least 7 days after hospital admission;
Cox Proportional Hazards: 
with and without benefiary 
MSSP
Negative Binomial with 
offset: with and without 
benefiary MSSP




ACO Characteristics as Moderators 
 ACO cohort: start year performance year 2013 (includes 2012 start dates) or 2014 
 Experience: number of years in MSSP  
 Primary care focus: more than 10 primary care providers per 1000 beneficiaries 
 Specialty focused: more than 10 specialists per 1000 beneficiaries 
 Size: more than 20,000 beneficiaries. 
 MSSP penetration: % of patients discharged from the hospital who are aligned with 
any MSSP ACO. 
 Care continuity: beneficiary assigned to Hospital ACO 
Covariates 
Covariate Specifications 
Patient control variables provided by GWTG include age, race, gender, Hispanic 
ethnicity, dual eligible status, pertinent medical history, and stroke severity as measured by the 
National Institutes of Health Stroke Scale (NIHSS) (linear, 0–42)
56
 as well as health and 
ambulatory status at discharge. Specifically, models included five-year age categories as well as 
the interaction of sex and age group to allow for nonlinear effects of age.
21,32
 Race/ethnicity 
(categorical) includes White, Black, Hispanic, Asian, Other. Binary indicators for risk factors 
(current smoker, hypertension, diabetes, myocardial infarction, heart failure, and atrial 
fibrillation) and Medicaid dual eligibility are used. Health status was measured by laboratory 
values (continuous) including body mass index, systolic blood pressure, diastolic blood pressure, 
heart rate, low density lipoprotein, high density lipoprotein, A1C, and the international 
normalized ratio. Ambulatory status was measured by a response of “unable to ambulate” 
(binary) and the Modified Rankin Scale (categorical, 0–5) for disability. Chronic Kidney disease 
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was identified by estimated creatinine clearance
70
 less than 60 using: Glomerular Filtration Rate 
(GFR) = 175 × standardized Scr
−1.154 × age−0.203 × 1.212 [if black] × 0.742 [if female], where GFR 
is expressed as mL/min/1.73 m2 of body surface area41 and Scr is expressed in mg/dL.  
Hospital factors from the GWTG registry data include number of beds (continuous), 
annual stroke admisssions, Census region (categorical), and binary indicators for rural status, 
teaching hospital, and primary stroke center. Market factors obtained from the AHRF include 
continuous measures for county proportion over age 65; number of primary care physicians per 
10,000 residents; proportion of households in poverty; total population (log); and number of 
hospice providers per 10,000 residents (Aim 3 only). Models also control for county Area 
Deprivation Index (log). Covariates were tested for collinearity (variance inflation factor >10) 
and as a result the GWTG mortality risk prediction score was excluded from the model.  
Multiple Imputation Using Fully Conditional Specification 
Excluding observations with missing covariate values (Complete Case Analysis) can 
introduce bias into estimates if these values are not missing completely at random. The potential 
for bias increases with the proportion missing, and NIHSS stroke severity score has the highest 
proportion missing (28%). In this cohort, missing NIHSS is correlated with hospital and patient 
characteristics, and the CCA approach could result in biased estimates. Multiple imputation of 
missing values relaxes the CCA assumption to require the values to be missing at random 
conditional on the other covariates. Because of the rich patient and hospital data available in the 
registry, this approach is likely to minimize the potential for bias by predicting the value of the 
missing variable using the other covariates available.  
Exceptions to the use of multiple imputation include 1) observations missing patient-level 
variables with less than 1% of values (race and gender) missing are excluded (n<100); 2) missing 
single items in the medical history, where missing were imputed as “no” per GWTG standard 
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protocol because it is a common practice to only report in the affirmative during data collection; 
3) observations missing hospital-level variables were excluded due to the lack of causal 
connections within the available information (n=0); and 4) missing market variables from the 
ARHF were imputed to the most recent year available and if none were available the 
observations were excluded (n<400).  
Multiple imputation by fully conditional specification (FCS MI) is a powerful and 
statistically valid method for creating imputations in large data sets that include both categorical 
and continuous variables.
71
 This method defines a separate conditional distribution of each 
imputed variable, and the user can define the variables on which to condition the distribution. 
For each imputed variable, I included all predictors that would be included in the main model 
(except hospital referral region fixed effects) as well as the clinical outcomes. Variables with 
skewed distributions (e.g., lab values) were log transformed for imputation and then 
exponentiated. Variables with limited range were imputed using logistic or ordinal logistic 
regression models. Numerical summaries were used to compare and confirm the similarity of the 
distributions between imputed values and observed values. 
Main results were run in a single data set with missing values estimated using multiple 
imputation using the Fully Conditional Step method, which involved two phases: the preliminary 
filled-in phase followed by the imputation phase. First, missing values are randomly generated 
using a normal distribution to provide starting values for the conditional imputation. In the 
second stage, a statistical model unique to each variable was used to impute missing values for 
the imputed variable. In this study, the missing values for each variable were imputed using 
logistic regression for binary variables and linear regression for continuous variables. In addition 
to the covariates in the primary model, the dependent variables and auxiliary health status 
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variables (e.g., ambulatory status, dysphagia results, and mortality risk prediction score) were 
included in the imputation models. 
This method introduces a source of error in the effect estimates due to the uncertainty 
involved in these imputed values into the analysis. To test the consistency of the estimates across 
multiple data sets with independently imputed values, I aggregated results of models estimated 
across five data sets with values computed in the same manner. Using five imputations resulted 
in a relative efficiency for imputed values around 99% and additional imputations would have 
little effect on the distributions. The combined estimated effect is the average of the estimates 
generated within in each imputed data set. The variance of that overall estimate is a function of 
variance within each imputed data set and the variance across the data sets. The between 
variation represented about 3% of the total variation in estimates and the combined estimated 
effects were similar in direction, magnitude, and significance to the estimates in the first 
imputation. For example, the coefficient for ACO-alignment is 0.0438 (CI=0.0167, 0.071) 
aggregated over five imputed datasets compared to .0408 (CI=0.0143, 0.0673) in the first 
imputed dataset. Because there was no meaningful difference, presented results are for the first 
imputation unless otherwise noted. 
2.7 General Analytic Approach 
I employed a difference-in-difference design to estimate the differential changes in the 
outcome among MSSP hospitals from the baseline to post MSSP relative to the concurrent 
change in the control group. Because the MSSP is a voluntary program, providers that decide to 
participate may be different from providers that do not in ways that impact outcomes. If 
providers that provide higher quality care are more likely to join ACOs and have better patient 
outcomes, then a model that does not control for the difference in quality would overestimate the 
effect of the program. The difference-in-difference method will reduce the potential for bias by 
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controlling for these unobserved differences between the treatment and control groups at baseline 
that do not change over time.
5,33,72
  
A key assumption of this difference-in-differences analysis is that the difference in 
adjusted outcomes between the MSSP group and the non-MSSP group in the pre-contract period 
would have remained constant in the post-contract period in the absence of the MSSP. Although 
I was unable to demonstrate comparable trends given the few time periods prior to MSSP 




Evaluation of each outcome will use a difference-in-differences framework with the 
general formula: 
   (Eqn 1) 
 
where L is the outcome of individual I treated in hospital j at time t, f is the link function, X is the 
vector of case-mix covariates, uj are HRR fixed effects, vt are year and month fixed effects, D
1
j is 
a dummy variable taking the value 1 for hospitals that become part of the MSSP program, D
2
t 
represents dummy variables taking the value 1 for discharges after the hospital initiated the 
MSSP program, and ε is an individual-specific error term. The coefficient of interest is δ, the 
difference-in-differences estimator for the post MSSP relative to the baseline period. The result 
is interpreted as the population average effect of treatment on the treated group. 
For each outcome, two models will be generated: 1) the hospital MSSP difference-in-
difference model without controlling for beneficiary MSSP status; 2) the hospital difference-in-
difference model including a dummy variable for beneficiary MSSP status. In the first model, δ 
represents the total effect of hospital MSSP, including the impact that occurs through the 
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outpatient care pathways for MSSP beneficiaries, relative to patients discharged from non-MSSP 
hospitals. In the second model, δ represents the net effect of MSSP hospitals through acute care 
pathways independent of the MSSP beneficiary effect though primary care pathways, relative to 
patients with neither MSSP hospital or MSSP beneficiary exposure (control). Variation in the 
effect by ACO characteristics was evaluated by adding an interaction with DD to the model not 
controlling for beneficiary MSSP status. In the model evaluating variation by ACO 
characteristics, Census division fixed effects were used as opposed to HRR fixed effects due to 
the limited number of HRRs (less than 1 in 4) with more than 1 ACO.  
The wide variation in regional usage patterns may introduce bias into the estimate for the 
effect of MSSP because MSSP penetration varies geographically in ways that are correlated with 
outcomes. A hospital fixed effect would control for the unobserved hospital-level characteristics 
that impact use directly following discharge; inpatient and SNF use over the course of the year 
following discharge is expected to be driven by regional variation in physician practices patterns 
and cultural norms more so than hospital-level variation.
73
  
Dartmouth Atlas defined 306 Hospital Referral Regions (HRRs) nationwide, built around 
cities where major cardiovascular and neurosurgeries can be performed. Like cardiovascular and 
neurosurgery, acute stroke care is highly specialized, and we expect the use patterns for this 
cohort of stroke patients to align well with the hospital referral regions. In addition, the variation 
within and between hospitals was assessed using the intraclass correlation coefficient (ICC). The 
lower the ICC score, the less likely that unmeasured hospital-specific effects influence the 
outcome estimates. Variation between hospitals explained less than 5% of the variation after 
controlling for Hospital Referral Region fixed effects. Thus, the statistical models include a HRR 
fixed effect to control for the unobserved, time-invariant factors within HRRs. Year and month 
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fixed effects are also included to account for changes over time and seasonal variation in 
outcomes within HRR.
74
 The models evaluating variation in the effect by ACO characteristics 
include state fixed effects rather than HRR because only 20 out of 88 HRRs had more than one 
ACO, resulting in very little within HRR variation across ACOs. 
Changes in the composition of the patient populations within treated and control groups 
over time may cause confounding if these changes are correlated with outcomes. Although prior 
analyses have not found meaningful differences between the ACO and non-ACO patient groups, 
potentially because patients are passively assigned to an ACO by CMS and are often unaware of 
their ACO status,
5,21,27,29,75
 this potential bias is mitigated in this study by controlling for patient-
level characteristics including age, race, and dual eligibility (which also help control for case mix 
and socioeconomic status) as well as county measures of socioeconomic status (e.g., poverty 
rates) and access (e.g., providers per capita).  
The high mortality rate in this population raises two potential sources of bias in 
estimating the differential change for use outcomes. 1) differential loss of follow-up (non-
informative censoring) and 2) the change in the intensity of acute care services as patients 
approach the end of life (informative censoring). Although the first concern is mitigated by 
incorporating time at risk into the model, informative censoring would require methods to 
decompose the total effect to assess the effect on rates of use independent of the effect due to 
informative censoring (mortality).
76
 Differential mortality rates over the follow-up period were 
assessed visually using Kaplan Meier curves and statistically using a cox proportional hazards 
model. Because no evidence for a survival benefit was found, traditional methods were used to 
account for differential, non-informative censoring.  
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Aim #1: I hypothesize that MSSP participation will be associated with reductions in 
service use in the year following hospitalization for stroke. The primary measures of service use 
are discharge to home (registry), number of hospital admissions (IP claims), and Days Alive and 
Out of Hospital (DAOH) (IP claims) in the year following discharge. To test this hypothesis I 
used negative binomial models with log link to generate incidence rate ratios for each measure. 
For admissions and DAOH an offset (log [number of days follow-up/365]) was used to account 
for time at risk during the follow up period.  
Aim #2: The objective of this aim is to evaluate the association of MSSP with health 
outcomes. I hypothesized that MSSP will be associated with reduced rate of rehospitalization, 
recurrent stroke and all-cause mortality within one year. To test this hypothesis, cox proportional 
hazards models were used to estimate a difference-in-difference for probability of survival at 
time t: 
 
λ(t|Xij) = λ0(t) exp(Xβ)      (Eqn 3) 
 
In survival analyses, models were stratified by HRR to allow the baseline hazard rate to 
vary by HRR rather than a dummy variable approach, which can introduce bias.
77
 In this 
approach, the fixed effects are absorbed into the unspecified function of time and fixed effect 
coefficients are not directly estimated. Proportional hazards assumptions were assessed visually 
using Kaplan Meier survival curves and plots of the log of negative log of the estimated survival 
functions by log of time as well as global tests for the models predicting each outcome and the 
assumption was not violated.  
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Aim #3: The objective of this aim was to test the association of MSSP with hospice use 
(across all settings) among patients with Limited Life Expectancy in the year following 
hospitalization. There are two specific hypotheses under this objective: 1) MSSP would be 
associated with increased hospice use (across all settings) among patients with Limited Life 
Expectancy in the year following hospitalization and 2) MSSP would be associated with 
increased length of use among hospice users. 
To test the first hypothesis, I generated difference-in-difference estimates for the effect of 
ACO status on a binary indicator of hospice use, controlling for all covariates as in Aims 1 and 2 
with the addition of number of hospice providers in the county (AHRF). 
Logistic regression is preferred over survival analysis because earlier hospice initiation 
relative to hospitalization is not necessarily preferable—it is the timing relative to death that has 
been associated with quality. It is possible that ACOs improve hospice use through the pathway 
of improved survival, more time “at risk” of referral leads to greater referrals. This pathway still 
results in improved hospice use and quality of death, and thus the interpretation of the probability 
of hospice use is preferred over a hazard ratio. In addition to the logistic regression model within 
one year, I also used a negative binomial model with log link and offset to account for censoring 
to generate incidence rates ratios for hospice use over two years from hospitalization. The 
direction and significance of the estimates in both analyses were the same, so only the logistic 
results are presented.  
Improved timing of hospice enrollment was measured by reductions in short stays (<7 
days prior to death) and increased median hospice stay among hospice users who are deceased or 
discharged alive during the follow-up period. Patients surviving less than seven days from the 
index hospital admission date were excluded from the short stay model because they were not 
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eligible for the outcome. Logistic regression was used to estimate the average differential effect 
on the probability of a short stay, and quantile regression was used to estimate the distributional 






 percentiles. In addition, I used a 
generalized linear model to estimate the mean effect on hospice days.  
For binary outcomes, a logit link will be applied to a difference-in-difference estimation: 
 
Pr(Yijt=1|Xijt) = exp(Xβ)/[1+exp(Xβ)]     (Eqn 2) 
 
Average marginal effects were generated using the method of recycled predictions. 
Copies of the observed data were created for each group of interest: where both beneficiary 
MSSP and hospital MSSP are 0 (referent); where a hospital MSSP is 1 and beneficiary MSSP is 
0; and where beneficiary MSSP is 1 and hospital MSSP is 0. Two sets of these groups were 
created where LLE=1 and LLE=0 for a total of six comparisons. The differential effects were 
generated by subtracting the predicted probability in the referent group from the treated groups 
among LLE and not-LLE for four treatment effects: hospital MSSP and beneficiary MSSP in 
LLE; hospital MSSP and beneficiary MSSP in not-LLE.  
To generate confidence intervals around the predicted probabilities, I used bootstrapping 
to generate 100 random samples from the observed data. I ran the model within each sample to 
generate 100 sets of coefficients. I then used those coefficients to generate 100 predictions for 










CHAPTER 3. IMPACT OF ACCOUNTABLE CARE ORGANIZATIONS ON USE, 
CARE, AND OUTCOMES: A SYSTEMATIC REVIEW 
3.1 Introduction  
Since 2010, at least 900 Accountable Care Organizations (ACOs) have formed over 
1,300 payment contracts with public and commercial payers, managing care for 10% of the 
people in the U.S. population.
1,2
 ACO growth (both organizations and contracts) is likely to 
continue given the Centers for Medicare & Medicaid Services (CMS) goal of making 50% of all 
payments value-based by 2018 and the growing support of commercial payers toward value-
based payment arrangements.
78
 Although Medicare is the largest single payer of ACO contracts, 
commercial ACO contracts collectively represent about 60% of the 32 million ACO patients 
nationwide as of March 2017.
79,80
 Furthermore, 10 states had implemented Medicaid ACO 
programs as of January 2017, and at least 11 more are pursuing contracts.
81
 Given this growth of 
ACOs in Medicare and non-Medicare settings, a better understanding of the systematic impacts 
on care and outcomes across payers is needed.  
In the ACO model, providers across care settings voluntarily assume joint responsibility 
for the overall costs and quality of care of a defined population. However, financial performance 
is highly variable across ACOs, payer programs, and patient populations. The average savings 
generated by Medicare ACOs are nominal at best, with reductions of a $113 to $420 per 
beneficiary year in the Physician Group Provider Demonstration (PGPD) and 2012 Pioneer or 
Medicare Shared Savings Program (MSSP) cohorts, though no significant decrease was found 
among more recent cohorts or the Advance Payment ACOs.
5,27,32,75,82,83
 Greater savings are 





 Of 287 ACOs with commercial contracts in 2014, only 12 
published the financial outcomes, with 11 reporting reductions in spending between 2% and 
12%; for example, the Alternative Quality Contract (AQC) and the Collaborative Accountable 
Care (CAC) model generated savings of 8.8% and 5.7%, respectively.
78,85
 Despite nominal 
reductions in spending, the ACO strategy may increase total costs given the investment in 
technology and infrastructure required to implement the ACO contract and bonuses paid out to 
high performing groups.
27,86
 For example, the Pioneer program resulted in a net savings of just 
0.4% after accounting for bonus payments.
5
  
Given the limited cost reduction to date, the ACO experiment may lose momentum if the 
promise to improve non-financial outcomes does not come to fruition. The current body of 
evidence supporting the consistency and generalizability of ACO impacts on care and outcomes 
across payers has not been evaluated. This study aims to fill that gap by systematically reviewing 
studies that assess the association of public and commercial ACOs with health services use, 
processes of care, and outcomes of care.  
3.2 Conceptual Model 
An ACO is conceptualized as a payer-provider partnership designed to improve quality of 
care and outcomes while reducing per capita costs for a defined population across the continuum 
of care.
87
 ACO contracts align economic incentives with these goals to promote coordination of 
care, population health management, and care management programs (Figure 8). The 
implementation and effectiveness of these innovations will vary across ACOs due to provider 
group characteristics, including provider participation and governance structure, IT infrastructure 
and patient population, and contract incentives.
88,89
  
By implementing care coordination strategies, ACOs may improve care transitions and 
reduce waste or duplication of services across the care continuum;
90,91
 examples of potential 
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interventions ACOs may implement include improvements to hospital discharge planning and 
medication reconciliation.
92,93
 ACOs build these interventions on a foundation of advanced 
health information technology to proactively manage the health of their patient population and 
increase provider and beneficiary engagement.
94-96
 In addition, ACOs shift care from hospitals to 
low-cost settings by creating integrated clinical teams for complex patients that focus on 
prevention, disease management, and self-care as well as behavioral or social determinants of 
health (McClellan et al., 2014).
97,98
 Through the systematic adoption of patient-centered medical 
homes, the chronic care model, and other evidence-based care practices.
99-101
 ACOs are expected 
to reduce use of low-value services (e.g., diagnostic tests and imaging) and increase use of high-
value services (e.g., preventive care, medication management, and palliative care). As a result of 
this systematic reorganization of care processes, ACOs are hypothesized to improve quality of 
care as well as population health outcomes while reducing costs through reduced inpatient use.  
In addition to variation in ACO group characteristics, variation in the payer contracts 
(e.g., quality measurement and financial incentives) may motivate different health system 
innovations to improve health information technology and care processes. ACO contract 
components include financial accountability, quality measurement, and population health data 
sharing.
102-104
 First, ACO programs transfer some degree of risk for the cost of care for a defined 
population to a provider group. Although over half of private contracts include some form of 
downside risk, most Medicare ACOs participate in shared savings only tracks.
105,106
 Second, 
CMS prescribes quality metrics for Medicare ACOs, but non-Medicare contracts vary in the 
measures used to evaluate care quality.
107
 Shared savings or bonus payments are generally 
contingent on achievement thresholds, growth rates, or benchmark comparisons.
105
 Third, to 
improve population health, incentives are often linked to appropriate investments in 
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infrastructure and quality reporting. These three principles rely heavily on integrated information 
technology systems to share data both across providers within the ACO as well as between the 
payer and the ACO.
88,108
  
The value proposition of ACOs has two components: reducing costs and improving 
processes of care and outcomes. Despite the common goals, ACO contracts are inherently 
heterogeneous in the degree of risk, quality metrics reported, and level of support for population 
health. This review acknowledges the heterogeneity across payer programs and definition of an 
ACO for this study was intentionally inclusive to compare the quality of evidence for use, 
processes, and outcomes across payers.  
3.3 Methods 
Search Strategy 
We performed an electronic search of PubMed from January 1, 2010, to November 5, 
2016, for U.S. studies that reported the effect of ACOs on use, processes of care, and outcomes. 
We used combinations of search terms for accountable care, Medicare Shared Savings, physician 
group, and Pioneer ACO to obtain an initial list of eligible articles as follows:  
"accountable care" OR "MSSP" OR "Medicare Shared Savings" OR "Physician Group" 
OR "Pioneer ACO" AND (("2010/01/01"[PDat] : "2016/10/06"[PDat]))  
Published abstracts of all articles identified in the search were reviewed to determine 
which ones reported empirical findings related to the ACO model. We focused on studies that 
explicitly assessed non-financial impacts of payer contracts with provider-led ACOs. As we 
selected primary documents or review articles, we used snowballing to identify related articles. 
Following the formal search, we added newly released articles and CMS evaluations that met the 




We included articles if they were: 1) original reports or systematic reviews of empirical 
results and 2) the author(s) assessed a relationship between ACOs and health services use, 
processes of care, or outcomes of care. Because the intention is to evaluate payment strategies in 
the context of the United States, international studies were excluded. Each article was reviewed 
independently by two reviewers (BGK and SBS) for inclusion criteria and quality. The two 
reviewers then discussed discrepancies in selection and made decisions by consensus. For the 
purposes of this review, an ACO was defined as a payer-provider contract in which: (1) the 
financial incentives target networks of providers who assume responsibility for cost and quality 
across the spectrum of patient care; (2) quality benchmarks are required to be met to receive the 
incentives; and (3) the financial incentives increase with efficiency across the patient population, 
as demonstrated in global budget or shared savings programs. This broad definition was used to 
incorporate the effects of programs that preceded the ACO terminology. Assessments of provider 
strategies for quality improvement within ACOs were excluded, as were pay-for-performance 
programs that do not target systems of providers or tie incentives to global efficiency. Articles 
with decision science models were excluded because they are designed to determine potential 
population impacts given what is known about efficacy rather than evaluate efficacy. 
Data Extraction and Synthesis 
Two reviewers (BGK and SBS) assessed the quality of each study using the Newcastle–
Ottawa Quality assessment scale for cohort studies independently. For scores that did not match, 
the reviewers came to a consensus after debate. Although all studies have limitations, studies 
were ranked high quality if they met the highest criteria for selection, comparability of controls, 
and outcome assessment (nine stars). Studies with one weakness identified in any of these 
categories are described as moderate quality, and those with more than one weakness are 
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described as low quality. Due to wide variation in ACO programs and outcome measures, results 
of studies are synthesized narratively as well as in a table by outcome (multiple measures of 
similar outcomes are combined for simplicity). Although the synthesis focused on quantitative 
results, qualitative studies were also summarized.  
3.4 Results 
Of the 1,890 total articles collected, 1,292 were not original research (e.g., interviews, 
commentaries, industry strategic analyses, responses to articles, case studies, final rule 
publications, and policy analysis), 489 did not study an ACO as the primary intervention, 69 did 
not assess non-financial outcomes, and two were duplicates (Figure 9). In addition to the 38 
included PubMed articles, 8 studies were identified from other sources, including four federally 
funded evaluations.  
Among the 42 articles identified (Table 3), studies of Medicare (N=24) programs 
included the Physician Group Practice Demonstration (PGPD), the Pioneer ACO program, 
Medicare Shared Savings Program (MSSP), and the Advance Payment Model; studies of 
Medicaid (N=5) programs included New York, Minnesota, Ohio, Oregon, and Colorado ACOs; 
studies of commercial programs or all-payer ACOs (N=13, one of which was a Medicare 
Advantage program—Aetna), the Blue Cross Blue Shield–Massachussetts Alternative Quality 
Contract (AQC), and the Cigna Collaborative Accountable Care (CCAC) model (Table 4). No 
literature review of this research question was identified.  
Most (27) of the included studies used 2 to 5 years of post-intervention data, while 15 
reported results after one year or less. Studies primarily used claims-based data sources and 
payer-tracked quality metrics, resulting in large sample sizes but limited measures of detailed 
patient and clinical factors. One study used institutional trauma registries.
26
 Special subgroups 
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studied included the elderly, pediatric, mental and behavioral health users, cancer, clinically 
vulnerable, tobacco users, and low income groups.  
Quality of Evidence 
All studies were retrospective and observational due to the inability to randomize ACO 
assignment. The quality of study design was assessed by the Newcastle Ottawa Quality 
assessment scale. Studies using a pre-post design with a control group were rated moderate or 
high quality based on the level of adjustment for covariates. The 24 studies of ACOs 
participating in Medicare programs had an average quality score of 8 stars. The 18 studies of 
non-Medicare ACO programs had an average quality score of 6.8 stars. Statistically significant 
effects relative to a control group are summarized from 27 peer reviewed studies and 4 federally 
funded evaluations reporting (Table 5), and studies with 8+ star quality rating are prioritized in 
the narrative. 
Use 
Among studies evaluating effects of ACO participation on use, outcomes included 
inpatient use (inpatient days, hospital readmissions, intensive care unit or emergency department 
use), outpatient use (primary care visits, follow-up visits, physician services), post-acute or 
hospice care, and drug use.  
Medicare: Medicare ACO programs including PGPD, Pioneer, and MSSP were 
consistently associated with reduced inpatient use and emergency department use, however there 
was no evidence of a difference among subgroups of mental health users or cancer 
patients.
5,25,27,32-34,75,82,84
 The 2012 cohort of ACOs participating in MSSP had reduced acute 
inpatient care and discharges to facilities other than home, though these findings were not 
statistically significant within the first year of performance for the 2013 and 2014 cohorts.
109
 The 
PGPD was associated with reductions in readmissions, however the MSSP was not associated 
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with reductions in 30-day hospital readmissions except among patients discharged to a skilled 
nursing facility (SNF).
82,110
 MSSP ACOs reduced preventable admissions for Asthma/Chronic 
Obstructive Pulmonary Disorder.
27
 The PGPD reduced intensive care unit (ICU) use among 
cancer patients, but the Pioneer program was not associated with a reduction in ICU use in a 
small sample of patients hospitalized for trauma.
26,84
 
No evidence was found for a reduction of discretionary cardiovascular imaging and 
procedures as an indicator of low value service use in the PGPD.
31
 Although multiple studies of 
the Pioneer program reported reductions in physician procedures, imaging, and other indicators 
of low-value care, there was no differential change in low-value service use among any of the 
MSSP cohorts.
5,26,27,29
 An evaluation of the Advance Payment Model found that imaging, tests, 
and procedures increased from baseline relative to comparison markets.
83
 
The most thorough study of the Pioneer program found significant effects on outpatient 
care including reductions in primary care visits, post-acute care (SNF, home health), and hospice 
use and increased follow-up visits within seven days of hospital discharge, an indicator of care 
coordination.
5
 For MSSP, the sole study evaluating the impact on outpatient care patterns found 
no association with mental health–related outpatient or follow-up visits.
25
 The 2012 MSSP ACO 
cohort was associated with reduced length of SNF stays, though these findings were not 
significant within the first year of performance for the 2013 and 2014 cohorts.
109
 Among cancer 
patients, PGPD reduced hospice use and led to a decrease in mean hospice days per hospice 
user.
84
 The Pioneer program did not significantly affect total prescriptions Medicare Part D filled 






Non-Medicare: The New York Medicaid program was associated with reduced 
emergency department use, rehospitalization, and readmissions within 90 days.
112
 Furthermore, 
duration of attribution to an ACO was associated with greater reductions in 30-day readmissions 
and inpatient days among pediatric Medicaid patients, though emergency department and 
pharmaceutical use increased with duration.
55,113
 The AQC was not associated with significant 
changes in inpatient or primary care among mental and behavioral health users, but it was 
associated with increased number of medication management visits and reduced probability of 
substance use disorder (SUD) medication use within a low-risk subgroup.
114,115
  
Processes of Care  
Among the studies assessing processes of care, primary outcome measures included 
Healthcare Effectiveness Data and Information Set (HEDIS) standards (chronic disease 
management, adult preventive care, and identification and treatment of behavioral and mental 
health disorders).  
Medicare: In PGPD, care quality improved significantly in 6 of 7 quality indicators 
including diabetes management, hypertension management, coronary artery disease prevention, 
and cancer prevention.
33,75
 In Pioneer ACOs, diabetes management improved by 0.8 percentage 
points, though there was no significant change in mammography screening in the first year.
116
 
No evidence of improvement in screening mammography, Diabetes Prevention Services, or LDL 
testing was reported within one year of MSSP implementation relative to controls.
27
 There was 
evidence of a significant reduction in the prevalence of mental health disorders among Pioneer 
ACOs, though this difference was not found in MSSP ACOs.
25
 The evaluation of Advance 
Payment ACOs found no consistent improvements in quality during the evaluation period.
83
  
Non-Medicare: After one year, AQC was associated with an increase of 2.6 percentage 
points in the proportion of eligible enrollees for whom quality thresholds for chronic care 
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management were met and an increase of 0.7 percentage points in the proportion of eligible 
enrollees for whom pediatric care thresholds were met.
117
 After two years, chronic disease 
management improved 3.7 percentage points (p<0.001); pediatric care improved 1.3 (1.8 among 
high need) percentage points, and adult preventive care improved 0.3 percentage points.
118,119
 
The quality of care for children in Partners for Kids Medicaid program improved significantly (P 




After the first year of implementation of the Cigna collaborative care model, providers 
reported no change in five quality of care measures.
121
 Over a period of three years, AQC was 
associated with improvement in three of five performance measures studied (nephropathy 
monitoring, LDL screening, and retinal exam, among individuals with diabetes), however this 
effect was not observed among the group of mental health service users.
114
 Identification and 
treatment initiation for SUD improved among a low-risk subgroup, though these effects were not 
significant among all SUD users.
115
 Of five preventive measures, only probability of cholesterol 
testing evidenced a spillover effect on the Medicare population.
122
 
Outcomes of Care 
Seven studies assessed either patient satisfaction or clinical outcomes in Medicare ACOs, 
but no study evaluated these outcomes in non-Medicare ACOs. For MSSP and Pioneer, overall 
ratings of care reported by clinically complex ACO patients improved significantly as compared 
with similarly complex patients in the control group.
123
 Medicare beneficiaries assigned to 
Pioneer ACOs reported higher mean scores for timely care and for clinician communication 
relative to both non-ACO FFS and Medicare advantage beneficiaries, resulting in an increase in 









Four studies assessed the impact of Medicare ACO programs on clinical outcomes 
including mortality. Among cancer patients, PGPD was associated with a significant reduction in 
patient mortality of 0.65 percentage points over five years, which is equivalent to a 5.6% 
reduction in mortality risk.
84
 In a nationally representative sample, the MSSP and Advanced 
Payment programs had no significant impact on mortality in the early years.
83,109
 Furthermore, 
no evidence of an association was found between MSSP and short-term clinical outcomes 





In this review, the evidence for the impact of ACOs on health service use, processes, and 
outcomes of care is mixed, however no evidence indicates that the incentives for cost reduction 
in ACOs resulted in negative impacts on processes or outcomes of care. The most consistent 
outcomes associated with Medicare ACOs are reduced inpatient and ED use as well as improved 
measures of adult preventive care and chronic disease management. Non-Medicare ACOs also 
found some evidence of improvement in care quality metrics— for example, AQC was 
associated with improved quality metrics (e.g., mental health, pediatric care, and chronic disease 
management) and a pediatric Medicaid program Partners for Kids was associated with 
improvement on composite quality measures, though the generalizability of findings for single-
state programs is unclear. The seven studies evaluating patient experience or clinical outcomes of 
care showed no evidence that ACOs worsen outcomes of care, but only four studies assessed any 
clinical outcomes, and those that did included only Medicare patients. 
This review highlights the need for high-quality evaluation of non-Medicare ACOs 
because variation in quality measurement may cause variation in the impact of ACOs. 
Commercial and Medicaid payers may choose to align their performance measures with 
 
49 
Medicare, but there is not a required standard set of metrics. Mandating quality metrics may 
stifle the motivation of physicians and administrators who do not believe in their validity, 
subsequently harming their overall performance.
124
 In addition, financial and quality data for 
commercial ACOs are proprietary whereas Medicare data are publicly available. As a result, 
little is known about commercial ACOs quality measurement and performance outside of the 
AQC. Although Medicare ACOs have not adversely impacted measured process-of-care 
outcomes, the increased focus on measureable aspects of care may reduce the time providers 
spend on unmeasured aspects resulting in unintended impacts on care and outcomes.  
These results suggest that more time may be needed to determine the impact of ACOs on 
patient outcomes. Improvements in processes of care were consistently demonstrated in studies 
of PGPD and Pioneer Medicare payment programs, however nearly 75% of the original Pioneer 
ACOs later shifted to MSSP tracks with reduced downside risk. As a result, the Pioneer ACOs 
not demonstrating high performance may not be represented in the literature. The Pioneer track 
attracted ACOs with greater experience in managing care while the MSSP tracks allowed 
nascent ACOs to gradually assume risk, and these systems may require years to fully implement 
care coordination strategies and affect change. The relative inexperience of the MSSP ACOs 
may explain why the early impacts on processes and outcomes measures are ambiguous. 
Furthermore, previous CMS programs like the Medicare Premier Hospital Quality Incentive 
Demonstration produced positive results at first only for top performers, but regression to the 
mean led to null results in the long term.
125
 Finally, fee-for-service still accounts for the vast 
majority of reimbursement within Medicare ACOs, which may preclude ACOs from maximizing 





As ACO payment programs further shift risk for the cost of care to provider groups, the 
impact on health outcomes should continue to be monitored.
104
 Shifting risk to providers has the 
potential to create tension between the incentives to control costs and the provision of the highest 
quality care for each patient. In the MSSP, ACOs initially share in the savings generated by 
efficiencies in care (Track 1), and then graduate to tracks with higher levels of risk. Although a 
limited-risk strategy was successful in attracting provider groups, greater risk sharing may 
produce more substantial changes in processes and outcomes of care. The number of Medicare 
ACO contracts with downside risk is increasing, with 10% of Medicare ACOs assuming some 
level of downside risk in 2017.  
These early results are valuable in predicting whether the current ACO movement may 
stagnate due to a lack of progress toward the triple aim of improving care for the individual, 
population health, and cost control.
126-130
 Prior to the emergence of ACOs, health maintenance 
organizations (HMO) and pay-for-performance (P4P) programs were hailed as the solution to the 
U.S. crises of escalating costs and declining health outcomes, but they fell short. The finding that 
ACOs do not reduce and may even improve some measures of patient satisfaction and perceived 
quality of care suggests that ACOs have not prompted the patient frustration associated with the 
HMO model, potentially due to the preservation of patient choice in providers in the ACO 
model, among other differences.
131
 Similar to ACOs, P4P programs have been associated with 
small positive effects on the process measures targeted, however neither model has demonstrated 
consistent effects on health outcomes.
72,132-135
 To improve population health and outcomes, ACO 
programs may need to incentivize measures of quality that are more closely tied to outcomes.  
The conclusions that can be drawn from this review are modest. No prospective trials 
have evaluated ACOs, and we were unable to synthesize the results of observational studies into 
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a meta-analysis due to the differences between studies in the payer programs, populations, and 
outcome measures evaluated. Unpublished sources were only searched through references of 
published articles. As a result, this review may be affected by negative publication bias. 
However, the relevancy of this topic to national health policy is likely to minimize the impact of 
this bias, as evidenced by the proportion and number of null findings published. Due to our 
intentional focus within the U.S. healthcare system, our search was limited to PubMed, the 
primary database for high-quality, peer-reviewed evaluations of U.S. healthcare policies and 
programs. This decision may have resulted in fewer studies than a search of multiple databases. 
Finally, looking at outcomes alone misses important information regarding what it takes to 
produce those outcomes. Evaluating the specific mechanisms is outside the scope of our review, 
and future work to synthesize existing evidence and identify optimal mechanisms is needed. 
The evidence for the effect of ACOs on care processes and outcomes is mixed, 
potentially due to the variability in contract incentives and outcome measures, but the incentives 
for efficiency within ACO contracts have not negatively impacted common care quality 
measures or patient satisfaction. Current trends in ACO contracts including increasing risk for 
provider groups and provider experience may magnify any impacts of ACOs on care processes 
and outcomes over time. Further studies are warranted to assess the downstream impacts of 































Potentially relevant articles Identified in 
PubMed using search algorithm (N=1890) 
 
Abstracts pulled on the basis of the Title 
(N=166) 
 
Alternative Sources (N=9) 
 References (1) 
 Federally Funded 
Evaluations (4) 






Full articles reviewed on the basis of abstracts 
(N=51) 
 
Papers that met eligibility criteria (N=46) 
 Original reports providing empirical 
results 
 Assessed the relationship between 



















Table 3. Summary of Articles and Reports Assessing Outcomes Associated with Accountable 
Care Organizations  
New 
ID 




Quantitative Analyses       
Peer-reviewed publications, control group   
1 2011 Song Z Alternative Quality Contract 1 Year 7 
2 2012 Claffey TF Aetna Medicare Advantage 
NovaHealth Collaboration  
4 Years 5 
3 2012 Colla CH Physician Group Practice 
Demonstration 
5 years 9 
4 2012 Salmon RB Cigna Collaborative Accountable 
Care model 
1 year 6 
5 2012 Song Z Alternative Quality Contract 2 Years 7 
6 2013 Colla CH Physician Group Practice 
Demonstration 
5 years 9 
7 2013 McWilliams JM Alternative Quality Contract 1-2 years 9 
8 2014 Chien AT Alternative Quality Contract 2 Years 7 
9 2014 Colla CH Physician Group Practice 
Demonstration 
4 years 9 
10 2014 McWilliams JM Medicare Pioneer and Shared 
Savings Program  
1 year 9 
11 2014 Pope G* Physician Group Practice 
Demonstration 
5 years 9 
12 2014 Song Z Alternative Quality Contract 4 years 7 
13 2015 Barry CL Alternative Quality Contract 3 years 8 
14 2015 McWilliams JM Medicare Pioneer Program 1 year 9 
15 2015 Nyweide DJ Medicare Pioneer Program 2 years 9 
16 2015 Schwartz AL Medicare Pioneer Program 1 year 9 
17 2016 Busch AB Medicare Pioneer and Shared 
Savings Program  
2 years 9 
18 2016 Colla CH
‡
 Medicare Pioneer and Shared 
Savings Program  
2 Years 9 
19 2016 Geyer BC Medicare Pioneer Program Inpatient 
Stay 
7 
20 2016 Herrel LA Medicare Shared Savings Program 30 days 8 
21 2016 Hewner S New York State Medicaid Program 90 days 7 
22 2016 Huskamp HA Alternative Quality Contract 3 years 7 
23 2016 McWilliams JM Medicare Shared Savings Program 1 year 9 
24 2016 Muhlestein D Public and Commercial ACOs 1 year 6 
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25 2016 Ramirez AG Medicare Pioneer Program 1 year 5 
26 2016 Stuart EA Alternative Quality Contract 3 years 9 
27 2017 Winblad U Medicare Pioneer and Shared 
Savings Program  
30 days 9 
28 2017 Zhang Y Medicare Pioneer Program 1 year 9 
29 2017 McWilliams JM Medicare Shared Savings Program 1 Year 9 
Federally Funded Reports    
30 2012 RTI* Physician Group Practice 
Demonstration 
5 Years 9 
31 2015 US GAO Medicare Pioneer Program 2 Years 6 
32 2016 L&M  Medicare Advance Payment ACO 5 years 9 
33 2016 L&M  Medicare Pioneer Program 3 years 7 
Peer reviewed publications, no non-ACO control group   
34 2012 Share DA Physician Group Incentive 
Program 
4 years 6 
35 2015 Kelleher KJ Ohio Medicaid Partners for Kids 
Program 
6 years 5 
36 2015 Christensen EW Minnesota Medicaid ACO  3 years 7 
37 2015 Singh S Medicare ACO Programs 1 Year 3 
38 2016 Christensen EW Minnesota  Medicaid ACO  3 years 7 
39 2016 Peiris D Public and Commercial ACOs 4 Years 4 
40 2017 McConnell JK Oregon and Colorado Medicaid 
ACO Programs 
2 Years 7 
41 2017 Song Z Alternative Quality Contract 7 Years 8 
42 2017 Narayan AK Medicare Shared Savings Program 3 years 6 
Qualitative Analyses     
43 2016 Chien    Alternative Quality Contract n/a n/a 
44 2016 Berenson Not Stated n/a n/a 
45 2016 Fullerton Medicare ACOs n/a n/a 
46 2016 Hefner Private ACOs n/a n/a 
Notes: ACO=Accountable Care Organization; US GAO=United States Government 
Accountability Office;  
*Papers use the same analysis, one is peer-reviewed   







Table 4. Description of ACO Programs Evaluated by Studies included in this Systematic Review 
Program 




BCBS-MA Alternative Quality 
Contract 
Time Frame 2005-2010 2008-2011 2009-present 
Description 
Mandated by the Medicare, Medicaid, 
and SCHIP Benefits Improvement and 
Protection Act of 2000 to improve care 
for Medicare FFS beneficiaries. 10 
participating physician groups across 4 
census regions, with risk adjustment 
using retrospective patient assignment 
National Medicare Advantage plan 
defined by collaboration between 
Aetna and NovaHealth to improve care 
for Medicare Advantage beneficiaries, 
prospective assignment. 
This initiative included Massachusetts 
provider organizations participating in 
Blue Cross Blue Shield HMO and POS 
plans. Unlike FFS based ACOs, only 
HMO and POS plan enrollees were 
eligible, and ACO attribution was 
determined by the designated primary 
care physician. 
Incentives 
Under the PGP Demonstration, 
practices could share a maximum of 80 
percent of savings they earned beyond 
the minimum savings requirement that 
was fixed at 2 percent. CMS compared 
the participating practice’s performance 
against a local comparison “control” 
group with respect to total per 
beneficiary expenditures for Medicare 
Parts A&B.  
The 3 year financial agreement 
included the current fee-for-service 
reimbursement plus an enhanced per 
member per month payment for 
achieving mutually agreed-on quality 
and efficiency goals (4 quality 
measures plus Hospital inpatient 
avoidable days or admissions per 
1,000). Shared savings component 
planned.  
Defining features include a global 
budget with annual spending growth 
limits, incentive payments to improve 
quality (up to 10% of revenue), and 
technical support for participating 
groups. Organizations receive quality 
bonuses that are based on 64 measures, 
including data on processes, outcomes, 
and patients’ experiences.  
Care Strategies 
Interventions included: chronic disease 
management programs, high risk/high 
cost care management, transitional care 
management, end-of-life/palliative care 
programs, practice standardization, and 
quality improvement programs.  
Provides care management services, 
including specialized programs such as 
the Aetna Compassionate Care 
Program for members with advanced 
illness. 
Uses the patient-centered medical home 
and enrollees designate a primary care 
physician. The PCP's organization is 
accountable for all enrollee services, 
regardless of whether the enrollee 
receives care from the PCP, the PCP's 
organization, or any other provider.  
Number of 
ACOs 
10 1 (750 Aetna Medicare members) 
1 (Blue Cross Blue Shield of 
Massachusetts network as of 2012) 







Table 4. Description of ACO programs evaluated by studies included in this systematic review (con’t) 
Program Cigna Collaborative Accountable Care Pioneer ACO Model Medicare Shared Savings  
Time Frame 2010 2012-2015 2012-2016 
Description 
A shared-savings accountable care model, 
similar to MSSP, 
with collaborative support from the payer 
across three geographically and 
structurally diverse provider practices in 
Arizona, New Hampshire, and Texas.  
Centers for Medicare and Medicaid 
Innovation (CMMI) developed the 
Pioneer ACO Model to test alternative 
design elements, including risk 
adjustment using prospective patient 
assignment.  
Providers continue to receive traditional 
Medicare fee-for-service (FFS) 
payments under Parts A and B, while 
assuming responsibility for a portion of 
the annual per beneficiary spending 
differential relative to benchmarks with 
risk adjustment using retrospective 
patient assignment 
Incentives 
Payer pays a care coordination fee in 
addition to support in informatics, care 
coordination, and consultation to 
participating practices. Payer also 
provides interim quality and cost results.  
The better a practice performs in 
comparison to its goals, the larger its care 
coordination fee for the following year.  
3 year contracts with a higher portion 
of shared savings and shared risk than 
MSSP tracks 1 and 2 with the same 
quality targets as MSSP. 
3 year contracts with levels of shared 
savings and shared risk: no risk in track 
1; 40%-60% of losses in track 2; and 40-
75% of losses in track 3. Of 418 
Medicare ACOs, 6 had enrolled in track 
II and 16 in track 3 for 2016. In order to 
qualify for a shared savings payment the 
ACO must meet 32 specified quality 
targets across four domains 
(patient/caregiver experience, care 
coordination/patient safety, preventive 
health, and at-risk population).  
Care 
Strategies 
Practices must commit to establishing an 
embedded care coordinator (registered 
nurse) position. Provider led Provider led 
Number of 
ACOs 1 32 (2013) 418 (2016) 






Table 5. Studies Assessing Use, Processes of Care, and Outcomes of Care by Significance Level in Medicare Only and Non-Medicare 
Settings 
 
Outcome Measure (direction of effect) Significant Difference No Significant Difference 





Inpatient use  (decrease) 6†, 11, 15, 18, 23
‡
, 29, 30  13*, 17*, 19, 20†, 26* 
Emergency Department Visits (decrease) 11, 15, 18, 30 21 3, 17* 






 21, 24 7, 14, 15, 17*, 20
†
, 23, 29, 32 
Intensive Care Unit (decrease) 6†   19  
 
Low Value Services and Imaging (decrease) 15, 16, 19   9
||







 Primary Care Visits (decrease) 15   17*, 26* 
Follow up visit after acute care (increase) 15   17*, 21, 32 
SNF/Home Health (decrease) 15, 29     
Hospice Referral and hospice days (decrease) 6†, 15     
Part D Prescriptions (increase)     28 
 
Processes of Care        
 
Preventive Care Metrics (improve) 11, 30 1, 5, 8, 22 7, 23 
  Chronic disease Management (improve) 11, 14, 30 1, 5, 7
¶
 4, 8, 23 
  Mental Health Care Quality (improve)   13*, 26* 17* 
  Value Based Purchasing (improve)     24, 25 
  Outcomes of Care       
  Patient Experience (improve) 11, 16   10 
  Surgical Complications (decrease)     20† 
  Mortality (decrease) 7†   20†, 29, 32 
  Notes: Results from studies without a control group were not assessed, and  
results from studies #2 and #13 (both studies of non-Medicare ACOs) are  
excluded because statistical significance was not assessed.    
  *Users of mental health services 
 
    †Cancer patients 
 
    ‡Asthma/Chronic Obstructive Pulmonary Disease 
 
    §Discharged to skilled nursing facility following hospitalization 
    ||Cardiovascular discretionary imaging and procedures 













CHAPTER 4. MEDICARE SHARED SAVINGS ACOS AND STROKE OUTCOMES: 
FINDINGS FROM GET WITH THE GUIDELINES–STROKE 
4.1 Introduction 
Since 2010, at least 900 Accountable Care Organizations (ACOs) have formed over 
1,300 payment contracts with public and commercial payers, and Medicare accounted for 563 of 
those contracts in 2017.
1-3
 ACO contracts aim to align economic incentives with coordination of 
care, population health management, and care management programs.
87,102-104
 The Centers for 
Medicare and Medicaid Services (CMS) implemented the Medicare Shared Savings Program 
(MSSP) to allow provider groups to retain a portion of the savings (or losses) generated by the 
coordination of care for Medicare fee-for-service (FFS) beneficiaries, within the FFS 
reimbursement structure. As a result of these contract incentives, ACOs are expected to shift care 
from high-cost inpatient settings to home and outpatient settings. However little is known about 
the impact on post-discharge inpatient use following ischemic stroke for elderly Medicare 
beneficiaries.  
At a cost of $30 billion annually, health services use remains high over the year following 
hospitalization for stroke, and post-acute care is typically provided in skilled nursing facilities 
(SNFs), inpatient rehabilitation facilities (IRFs), home health agencies, and/or outpatient 
rehabilitation settings.
7,24
 One in five Medicare stroke patients are readmitted within 30 days, 
with higher rates among patients with multiple chronic conditions.
24,33,44
 Post-stroke care 
delivery may be impacted by ACO strategies including discharge planning, care management, 





Reduced inpatient use is consistently associated with ACO alignment among Medicare 
beneficiaries.
5,27,53
 Reductions in discharge to facilities rather than home and greater per capita 
savings have been reported among among hospitalized and clinically vulnerable 
beneficiaries.
32,109,110,136
 The skilled nursing facility (SNF) is a common setting for post-stroke 
care, and reductions in 30-day hospital readmissions have been observed among hospitalized 
patients discharged to SNFs.
110
 In addition, implementation of care management programs may 
improve anticoagulant persistence and adherence impacting long term clinical outcomes (e.g., 
reduce recurrent stroke and mortality). 
Existing studies of MSSP using claims data have limited controls for case mix and 
severity, which are critical adjustment factors for assessment of clinical outcomes. Get With The 
Guidelines
®
–Stroke (GWTG–Stroke) was implemented by the American Heart 
Association/American Stroke Association (AHA/ASA) to improve the quality of care and 
outcomes for stroke and transient ischemic attacks by promoting consistent adherence to 
evidence-based guidelines. This national registry, which includes 2 million discharges since 
2003 at over 1,700 hospitals, provides a rich inventory of patient-level clinical factors and 
medical history to facilitate robust assessment of the impact of ACOs on stroke care.  
The objective of this study was to evaluate the association of the MSSP (hospital 
participation and beneficiary alignment) with use and clinical outcomes in the year following 
hospitalization for incident ischemic stroke. We hypothesized that MSSP ACOs would reduce 
post-discharge acute care use (e.g., discharge to facility rather than home, rehospitalization, 
inpatient days) after stroke without adversely impacting one-year clinical outcomes (e.g., 




The goal of this study is to compare one-year outcomes among two populations: 1) 
patients with incident stroke presenting at a hospital participating in an MSSP ACO contract 
(referred to as MSSP hospital) or assigned to an MSSP ACO by CMS (referred to as ACO-
aligned), and 2) stroke patients with neither MSSP exposure. To achieve this objective, the study 
used hospitalization data from the national registry GWTG–Stroke linked to Medicare FFS 
claims files in an observational, difference-in-difference study design.  
Data Sources  
Hospitalization records from GWTG–Stroke registry for admissions in years 2010 to 
2014 were linked to CMS denominator and inpatient claims files for years 2010 to 2015 using a 
validated algorithm.
57
 GWTG–Stroke is a high-quality data source for a sample with similar 
characteristics to the national Medicare stroke population and includes patient-level data on 
patient clinical risk factors, diagnostic testing results, and in-hospital outcomes as well as 
hospital characteristics including ownership, stroke center status, teaching hospital status, 
number of beds, rural status, and Census region.
58-60
 These data were merged with CMS MSSP 
provider- and beneficiary-level files for performance years 2013 and 2014, the Area Deprivation 
Index (ADI),
137
 and the Area Heath Resource File (AHRF) for years 2010 to 2014 to obtain 
county-level socioeconomic characteristics. Inpatient claims data available through September 
2015 enabled follow-up for outcomes beyond December 2014. 
Study Population 
The sample included Medicare FFS patients hospitalized in a hospital participating in the 
GWTG–Stroke registry between January 2010 and December 2014 who were age 65 or older 
with a physician-adjudicated diagnosis of ischemic stroke and linked to CMS claims. Duke 
University institutional review board determined that the study did not involve human subjects 
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and was thus exempt from review. Quintiles is the data collection coordination center for the 
American Heart Association/American Stroke Association Get With The Guidelines
®
 programs. 
Exclusion criteria include prior stroke, admission year greater than discharge year, missing all 
prior medical history, or registered at sites missing more than 25% of registry data. Beneficiaries 
who linked to CMS FFS claims but were not FFS at the time of hospital discharge were excluded 
(N=24,124). Additional exclusions following linkage were patients with inpatient death 
(n=19,742), discharge disposition as Left Against Medical Advice (n=838), or missing AHRF, 
race, or discharge disposition (n=1,881). Finally, patients identified as limited life expectancy at 
discharge (discharge to hospice; comfort measures only; National Institutes of Health Stroke 
Scale (NIHSS) score of ≥16; provider-reported limited life expectancy; or GWTG mortality risk 
prediction score > 0.15)
138
 were excluded (N=54,128) from the analyses presented in this chapter 
because the care trajectories are expected to be much different in this subgroup than in the rest of 
the sample, resulting in a final analysis sample of 251,605 (Figure 10).  
Measures 
Exposure: Separate ACO status measures for hospital and beneficiary community 
provider participation were obtained from the CMS MSSP provider- and beneficiary-level files 
for performance years 2013 and 2014. Two treatment groups were defined: 1) hospitals 
participating in an MSSP ACO contract and 2) ACO-aligned beneficiaries. The difference-in-
difference model included two key binary variables whose interaction identifies the effect of 
MSSP implementation. First, discharge records at hospitals participating in an MSSP in any year 
during the study period composed the ‘MSSP Hospital’ group. Second, discharge records at 
MSSP hospitals occurring after the date of the hospital’s MSSP contract initiation composed the 
‘Post-MSSP’ group. The interaction of MSSP Hospital and Post MSSP defined the differential 
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change from pre-MSSP to post-MSSP participation relative to the concurrent change in the 
group with no MSSP participation conditional on year. 
Second, ACO-aligned beneficiaries included all beneficiaries assigned to an MSSP ACO 
by CMS, including those hospitalized at non-MSSP hospitals. The binary indicator for ACO-
aligned beneficiaries identified patients assigned to any MSSP ACO in the quarter prior to 
discharge using the preliminary quarterly assignment.
55
 Because stroke patients may not survive 
long enough following discharge to be assigned using the claims algorithm, ACO assignment 
was drawn from the period prior to hospitalization to avoid selection bias for patients with short 
survival in the period directly following discharge.  
Study Outcomes 
Measures of acute care use in the year following discharge included 1) discharge to home 
(registry data), 2) number of all-cause hospital admissions, and 3) Days Alive and Out of 
Hospital (DAOH).
139
 DAOH is calculated as the number of days alive and on FFS and spent 
outside of a hospital or IRF. Clinical outcomes in the year following discharge included time 
(days) to 1) all-cause rehospitalization, 2) recurrent stroke, and 3) all-cause mortality. A 
recurrent stroke was identified by a principal diagnosis on an inpatient claim including ICD-9 
codes 430, 431, 432, 433.x1, 434.x1, or 436 for a hospitalization or observation stay in the year 
following discharge.
66
 All-cause mortality rather than stroke-specific was included because a 
high proportion of deaths (44%) following stroke are due to non-stroke causes.
67
 Days of follow-
up were censored at the first non-FFS day after discharge, one year of follow-up, death, or end of 





Patient, Hospital, and County Characteristics 
Patient data provided by GWTG include age, race, gender, Hispanic ethnicity, dual 
eligible status, medical history, stroke severity as measured by the National Institutes of Health 
Stroke Scale (NIHSS), and health status at discharge. Measures of health status included 
laboratory values (continuous), unable to ambulate (binary), and the Modified Rankin Scale 
(categorical). Chronic kidney disease was defined using estimated creatinine clearance 
(categorical).
70
 Due to the high levels of missing values for NIHSS and measures of health 
status, excluding these observations could introduce substantial bias to the model. Patient 
covariates missing more than 1% of values were imputed using multiple imputation by fully 




Models include five-year age categories as well as the interaction of sex and age group to 
allow for nonlinear effects of age.
21,32
 Race/ethnicity categories includes White, Black, Hispanic, 
Asian, and Other. Binary indicators for risk factors at time of stroke hospitalization (current 
smoker, hypertension, diabetes, myocardial infarction, heart failure, and atrial fibrillation) and 
Medicaid dual eligibility are used. Hospital factors include number of beds (continuous), Census 
region (categorical), and binary indicators for rural status, teaching hospital, primary stroke 
center, and for-profit ownership. Market factors obtained from the AHRF include continuous 
measures for proportion over age 65, number of primary care physicians per 10,000 residents, 
proportion of households in poverty, and total population (log).  
ACO Characteristics 
ACO characteristics included year of entry into ACO (2012, 2013, or 2014), and ACO 
experience (> 1 vs. ≤ 1 year in MSSP), primary care focus (> 10 vs. ≤10 primary care providers 
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per 1000 beneficiaries), specialty focused (> 10 vs ≤ 10 specialists per 1000 beneficiaries), and 
size (>20,000 vs ≤ 20,000 beneficiaries). Two additional binary measures were also evaluated: 
MSSP market penetration (> 30% vs. ≤ 30% of hospital discharges aligned with any MSSP 
ACO), and ACO care continuity (beneficiary assigned vs. not assigned to the same MSSP ACO 
in which the hospital participates).  
Analyses  
A difference-in-difference (DD) design was used to estimate the changes in the outcome 
in the ACO group from the baseline to the post-ACO periods that differ from the concurrent 
change in the control group. Because the MSSP is a voluntary program, providers who decide to 
participate may differ from providers who do not in ways that impact the outcomes. If providers 
who provide higher quality care are more likely to join ACOs and have better patient outcomes, 
then a model that does not control for the difference in provider quality would overestimate the 
effect of the program itself. The DD method controls for unobserved differences between the 
treatment and control groups at baseline that do not change during the study period, an 
assumption supported in prior studies.
5,21,27,29,32,33,72
 The interaction of MSSP Hospital and Post-
MSSP defines the differential change (DD) from pre-MSSP to post-MSSP participation relative 
to the concurrent change in the group without MSSP participation in a given year. 
For each outcome, estimates from two models are presented: 1) MSSP hospital DD not 
controlling for beneficiary MSSP status (Eqn 1); 2) MSSP hospital DD controlling for 
beneficiary MSSP status (Eqn 2).  
 
𝐿𝑖𝑗𝑡 = 𝑓(𝑎 + 𝛽𝑋𝑖 + 𝛽𝑋𝑗𝑡 +  𝛽𝐻𝑅𝑅𝑗 + 𝛽𝑌𝑒𝑎𝑟𝑡 + 𝛽𝐷𝑗 + 𝛿𝐷𝐷𝑡 + 𝑖𝑗𝑡)  Eqn 1 
𝐿𝑖𝑗𝑡 = 𝑓(𝑎 + 𝛽𝑋𝑖 + 𝛽𝑋𝑗𝑡 + 𝛽𝐻𝑅𝑅𝑗 + 𝛽𝑌𝑒𝑎𝑟𝑡 + 𝛽𝐷𝑗 + 𝛿𝐷𝐷𝑡 + 𝛾𝐴𝐶𝑂𝑖 + 𝑖𝑗𝑡) Eqn 2  
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where L is the outcome of individual i treated in hospital j at time t, f is the link function. In the 
first model, DD represents the total effect of MSSP hospital, for MSSP-aligned and non-aligned 
beneficiaries. The referent group in the former model includes MSSP-aligned beneficiaries 
hospitalized at non-MSSP hospitals. In the second model, DD represents the net effect of MSSP 
hospital participation (presumably through acute care pathways) independent of beneficiary 
MSSP alignment (presumably through primary care pathways). The referent group in the latter 
model consists of beneficiaries neither ACO-aligned nor hospitalized at an MSSP hospital. 
Variation in the effect by ACO characteristics was evaluated by adding an interaction with DD to 
the model not controlling for beneficiary MSSP status. 
Negative binomial models with a log link were used to estimate incidence rate ratios for 
use outcomes (e.g., discharge to home, admissions, DAOH). For admissions and DAOH, an 
offset for log of the proportion of follow-up time within one year after index discharge was used 
to account for time at risk during the follow-up period.
140
 Cox proportional hazards models were 
used to evaluate time to event outcomes (e.g., rehospitalization, recurrent stroke, mortality). 
The wide variation in regional usage patterns may bias our estimates if ACO penetration 
is correlated with regional rates of service use. Statistical models evaluated changes using 
Hospital Referral Regions (HRRs) fixed effects to control for the unobserved, time-invariant 
differences between HRRs. In survival analyses, models were stratified by HRR to allow the 
baseline hazard rate to vary by HRR rather than a dummy variable approach, which can 
introduce bias.
77
 Year and month fixed effects were also included to account for changes over 




The analysis sample included index hospitalizations for 251,605 unique beneficiaries 
who did not have limited life expectancy based on their stroke hospitalization record (Figure 10). 
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Eligible hospitalizations that linked to CMS FFS claims (N=352,318) were compared with those 
unable to link (N=222,818), including Medicare advantage hospitalizations and unlinked FFS 
hospitalizations. Patient demographics, medical history, clinical measures, and hospital factors 
were not substantially different (standardized difference <0.2) between the two groups except for 
older age and fewer West Census region hospitalizations (standardized difference =0.24) among 
FFS-linked.  
Table 6 compares the patient, hospital and country characteristics for beneficiaries 
discharged from MSSP hospitals (n=87,183) vs. non-MSSP hospitals (n=21,499) prior to the 
implementation of the MSSP program (January 2010 to April 2012). Prior to implementation of 
MSSP, standardized differences in patient characteristics were small in magnitude (<2 
percentage points), except patients at MSSP hospitals are more likely to have private insurance 
(e.g., Veterans Affairs or supplemental Medicare policy) with 40% relative to 35% in the non-
MSSP group. Relative to non-MSSP hospitals, MSSP hospitals were larger, more urban, more 
likely to be a teaching hospital, and located in counties with lower poverty rates and higher rates 
of primary care physicians. Differential changes in the MSSP group in the post-MSSP period 
were observed primarily among hospital and county characteristics rather than patient 
characteristics.  
Difference-in-Difference Results 
Table 7 shows unadjusted baseline rate ratios as well as unadjusted and adjusted 
differential changes in event rates for discharges from hospitals participating in MSSP versus not 
participating. Prior to the start of an MSSP contract, MSSP versus non-MSSP hospitals had 4% 
lower rates of discharge to home (Incidence Rate Ratio (IRR)=0.96; 95% Confidence Interval 
(CI)=0.94,0.98) and 4% higher rates of rehospitalization (Hazard ratio (HR)= 1.04, CI=1.02, 
1.05) within one year. Differential changes in event rates were not significant prior to adjustment 
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for covariates. In the adjusted DD model, MSSP versus non-MSSP was associated with a 5% 
differential reduction in discharge to home (IRR=0.95; CI=0.92, 0.98), however discharge from 
MSSP versus non-MSSP hospital was not significantly associated with differential changes in 
other outcomes. Among patients not discharged to home, 41.2% were discharged to SNF and 
53.2% were discharged to IRF among discharges at MSSP hospitals relative to 42.3% and 50.4% 
at non-MSSP hospitals.   
ACO-Aligned Beneficiary Results 
From the models controlling for beneficiary MSSP alignment, the adjusted DD estimates 
as well as the estimate for the association of MSSP-aligned beneficiaries with outcomes are 
presented for each of the clinical and use outcomes (Figure 11). Similar to the DD results, 
receiving stroke care at a MSSP versus non-MSSP hospital was associated with a 6% differential 
reduction in the rate of discharge to home (IRR=0.94; 95% CI= 0.92, 0.97). At a rate of 1.72 pre-
MSSP, a 6% change represents approximately 30 discharges per 1,000. MSSP versus non-MSSP 
hospital use was not associated with a differential change in the rate of subsequent hospital 
admissions, however, relative to non-aligned beneficiaries, ACO-aligned beneficiaries had 5% 
higher rate of subsequent hospital admissions in the year following stroke discharge (IRR=1.05; 
CI=1.02, 1.07). At a baseline rate of 1.72 per person year, this change would be equivalent to 86 
additional hospitalizations per 1,000 per person year. No significant associations were found 
with DAOH for either MSSP versus non-MSSP hospitals or ACO-aligned versus non-aligned 
beneficiaries. Among the clinical outcomes, the differential change in rehospitalization for 
MSSP versus non-MSSP hospitals was not significant, however ACO-aligned versus non-
aligned beneficiaries had 3% higher adjusted rate of rehospitalization (HR= 1.03; CI=1.00, 1.05). 





In the analysis exploring how ACO characteristics might moderate the effect of MSSP, 
only ACO size was associated with a significant (p <.05) difference in the effect of MSSP on 
rates of discharge to home. ACOs with more than 20,000 covered beneficiaries had higher rates 
of discharge to home relative to ACOs with less than 20,000 beneficiaries (IRR=1.04; CI=1.00, 
1.09). No significant differences were found by ACO start year, number of providers or number 
of specialists. Estimates for a heterogeneous effect due to care continuity, ACO market 
penetration, county area deprivation index, or county PCP supply were not significant. 
4.4 Discussion 
This study evaluated the association of the MSSP hospital participation or beneficiary 
ACO-alignment with use and clinical outcomes in the year following hospitalization for ischemic 
stroke. Rather than shifting post-stroke care to lower intensity care settings, hospital participation 
in MSSP was associated with a significant decrease in the rate of discharge to home, meaning 
greater use of other care settings like SNF and IRF for post–acute care, relative to hospitals not 
participating in MSSP. Compared with beneficiaries with no MSSP participation, ACO-aligned 
beneficiaries had increased risk of rehospitalization in the year following stroke. These 
unexpected results in this high-risk population could have implications for ACOs providing care 
to stroke patients as well as the implementation of MSSP.  
The observed increase in the number of hospital admissions in the year following 
incident stroke for ACO-aligned beneficiaries contrasts with evidence that ACOs reduce 
inpatient use.
4,5
 Contrary to our finding of an increase in discharge to facilities other than home, 
a different study found a reduction in discharge to facilities was found for all-cause 
hospitalizations among Medicare beneficiaries.
109
 However, the evidence is mixed for high-risk, 
hospitalized subgroups like stroke. For example, multiple studies that found reductions in 
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inpatient days failed to find reductions in all cause readmission rates.
5,27,109
 In fact, small but 
significant increases in 30-day readmissions were found among a subgroup of clinically 
vulnerable patients, in which stroke was a top diagnosis group.
32,136
 In this context, our findings 
suggest effects of MSSP on post-discharge acute care may not be consistent across diagnosis 
groups.  
Despite the differential increase in rate of admissions following stroke hospital discharge, 
we did not observe a corresponding increase in number of inpatient days among ACO-aligned 
beneficiaries. ACOs may be more effective in shortening inpatient length of stay through transfer 
to post–acute care rather than preventing subsequent admissions. Admissions for preventable 
causes account for less than 2% of 30-day readmissions following ischemic stroke, and a 
reduction in non-preventable admissions would not reflect appropriate care.
44
 In addition, 
increased admissions may be driven by increased use of IRF, which have been associated with 
improved patient outcomes, as opposed to less intensive care settings (e.g., skilled nursing 
facility or home health).
141
 Although we found no change in one-year clinical outcomes, further 
work is needed to understand how MSSP impacts quality of post–acute care and patient-centered 
outcomes.  
Both hospital participation and beneficiary ACO alignment contributed to changes in use 
at different points in the care trajectory; for example, hospital status was associated with 
discharge setting whereas beneficiary status was associated with subsequent admissions. In 
addition to improving internal care processes, ACO providers also employ external patient 
support personnel who have little interaction with providers’ day-to-day practices.
98
 Through 
these added programs, ACO-aligned patients may receiving different services and have different 
outcomes than non-aligned patients receiving similar care from the same ACO providers. 
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Despite the potential for improved care integration within an ACO providing both acute and 
primary care, we found no evidence of a benefit for patients aligned with the same ACO 
providing their acute stroke care. 
Current quality metrics and incentives in MSSP contracts may not be sufficient to 
generate changes in post-stroke care. Incident stroke patients compose a relatively small segment 
of an ACO population in a given year (less than 1%).
142
 As a result, changes in stroke care would 
only move the needle on per capita costs for large-magnitude patient-level savings. Early ACO 
savings have resulted from small shifts among large segments of the patient population rather 
than relatively smaller segments of high-cost patient groups.
143
 Of the 33 MSSP quality measures 
in 2013–2014, two relate to patients with ischemic vascular disease—targeting the completion of 
lipid profiles and low density lipoprotein control via use of aspirin or other anti-thrombotics.
144
 
Even when ACO strategies are not specific to stroke care, systemic changes may impact care for 
stroke patients. New quality measures that may impact patients with stroke are being phased in 
during 2017 to 2019, including 1) all-cause unplanned admissions for patients with multiple 
chronic conditions, 2) documentation of current medications, and 3) medication reconciliation 
post-discharge.
145
 The implementation of these measures may increase the impact of MSSP on 
care transitions and post–acute care. 
Limitations  
Our findings should be interpreted in the context of several limitations. MSSP provided a 
pathway for gradually assuming risk for nascent ACO systems, and these early results may not 
reflect the potential impact of systemic improvements that require years to implement fully. Our 
models controlled for health status at discharge, so our estimates would underestimate the total 
effect if acute care quality improved with MSSP, despite the high baseline quality of care at 
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participating hospitals. Larger hospitals are more likely to participate in the GWTG–Stroke 
registry, so the generalizability of these results to smaller, more rural institutions is limited.
58
 
Patient ACO alignment is not randomized, and assignment may be correlated with differences 
between the treatment and control group that are not captured by the observable characteristics—
for example, education level or socioeconomic status—however models were adjusted for 
county-level socioeconomic factors to mitigate the potential for bias.  
4.5 Conclusions 
MSSP is associated with a lower rate of discharge home. Reductions in acute care use 
observed in the general Medicare population may not translate to patients with stroke. Current 
quality metrics and incentives in MSSP contracts may not be sufficient to generate changes in 
post-stroke care. Population metrics that drive systemic integration and coordination may benefit 
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Table 6. Differential Changes for GWTG–Stroke Discharges from Hospitals Participating in 






Patient Characteristic Difference  Mean
Age, median (25th-75th 
percentiles) 79.0     (72,85)




Female 56.1         57.2         1.2 -0.8
Black 9.6           10.8         1.2 -0.7 *
Hispanic 3.9           3.8           -0.1 -0.2 *
Asian 1.9           2.2           0.3 -0.1 *
Medicaid 6.7           6.8           0.1 -1.2 *
Private Insurance 35.5         40.6         5.1 0.0 *
Inpatient Clinical Measures
NIH Stroke Severity Score 4.2           (3.9) 4.1           (3.9) -0.1 0.0
Unable to ambulate, % 12.0         13.0         1.0 -1.3 *
CHA2DS2-VASc  2+, % 98.5         98.5         0.0 0.1
Chronic Kidney Disease, % 49.2         49.3         0.1 -0.7
Body mass index, Kg/m2 27.3         (6.5) 27.2         (6.2) -0.2 0.0
Diastolic blood pressure, mmHg 71.5         (12.2) 71.4         (12.1) -0.1 0.1
Systolic blood pressure, mmHg 137.4       (21.0) 137.5       (20.8) 0.2 -0.1 *
A1C measurement (0-20), % 6.4           (1.4) 6.4           (1.4) 0.0 0.0
High Density Lipoprotein, mg/dl) 45.0         (14.6) 45.6         (14.5) 0.6 0.2
Low Density Lipoprotein, mg/dl) 97.9         (37.7) 97.0         (37.1) -0.9 0.7
Heart rate, beats per minute 78.6         (17.1) 78.6         (17.0) 0.0 0.0
International normalized ratio   
(0-25) 1.2           (.5) 1.2           (.5) 0.0 0.0
Medical History (%)
Atrial Fibrillation 21.6                   22.7 1.0 -0.9 *
Carotid Stenosis 4.2                       4.3 0.1 0.2
Diabetes 31.4                   31.3 -0.2 -0.7
Peripheral Vascular disease 5.3                       5.5 0.2 0.0
Hypertension 84.6                   84.8 0.2 -0.2
Smoking 11.3                   10.8 -0.5 0.5
Dyslipidemia 49.4                   50.3 0.9 0.0
Heart Failure 9.4                       9.7 0.3 -0.2
Transient Ischemic Sroke 10.3                   10.1 -0.2 0.3
Hospital Characteristics
Number of Beds 398.7       (270.9) 441.0       (277.6) 42.3 -0.7 *
Annual Stroke Admissions 310.2       (199.9) 354.5       (235.4) 44.2 12.7 *
Rural, % 6.1           2.8           -3.3 1.0 *
Teaching, % 53.0         68.2         15.2 -3.7 *
Region (%)
Northeast 24.8         32.63       7.9 3.0 *
Midwest 20.2         26.56       6.4 1.9 *
South 39.0         30.41       -8.6 -2.6 *
West 16.1         10.39       -5.7 -2.4 *
% or Mean (SD) % or Mean (SD)
Non-MSSP MSSP
Difference between MSSP 
and Non-MSSP in 
Precontract Period87,183 21,499
Differential 
Change in MSSP  
vs Non-MSSP
County Characteristics
Total Population (log) 12.7 (1.5) 13.0 (1.5) 0.3 1.4
Proportion Age 65+ 14.2 (3.9) 13.6 (3.4) -0.6 0.1 *
Proportion Households in Poverty 14.8 (5.2) 13.5 (5.0) -1.4 0.2 *
# Primary care physicians (per 10,000) 7.6 (3.0) 8.3 (3.3) 0.7 0.0
Poor functional status is a response of "unable to ambulate" on the Get with the Guidelines form. 
Notes: From the authors analysis of American Heart Association Get with the Guidelines-Stroke registry data linked with 
*p <0.05 regression coefficient on the interaction of hospital MSSP status and post MSSP contract initiation in the naive 
model with year fixed effects. 
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Table 7. Differential Changes in Event Rates During the Year Following Discharge from 
Hospitals Participating in an MSSP Versus Not Participating, Before and After MSSP Contract 
Initiation (2010–2014) 
 
Notes: PY=Person year; CI=95% Confidence Interval; DAOH=Days Alive and Out of Hospital; 
HR=Hazard Ratio; IRR=Incidence Rate Ratio; IRR were generated using negative binomial 
models with offset. Hazards ratios were generated using proportional hazards models. All 
models were adjusted for patient demographics, health status at discharge, medical history, 
hospital factors, county factors, no evaluation and management visit the year prior to incident 




Clinical Outcomes HR (CI) HR (CI) HR (CI)
Rehospitalization 0.64 (0.63,0.64) 1.04 (1.02,1.05) 1.00 (0.97,1.02) 1.02 (0.99,1.04)
Recurrent Stroke 0.08 (0.09,0.08) 1.01 (0.97,1.06) 0.97 (0.90,1.04) 0.97 (0.90,1.04)
Death 0.18 (0.18,0.18) 0.98 (0.95,1.01) 1.01 (0.96,1.06) 1.03 (0.98,1.08)
Utilization Outcomes IRR (CI) IRR (CI) IRR (CI)
Discharge to home 
(proportion) 0.49 (0.48,0.49) 0.96 (0.94,0.98) 0.92 (0.80,1.07) 0.95 (0.92,0.98)
Number of admissions 1.72 (1.69,1.74) 1.02 (1.00,1.03) 1.00 (0.97,1.02) 0.98 (0.98,1.03)
DAOH 353.48 (353.7,353.27) 1.00 (1.00,1.00) 1.00 (1.00,1.00) 1.00 (1.00,1.00)
Rate/PY (CI)
Rate/PY (CI)
Prior to MSSP  Post-MSSP 
Discharges at Non-
MSSP Hospitals
Ratio of MSSP                
vs Non-MSSP 
Unadjusted DD 
MSSP  vs Non-MSSP
























Panel A: Time to event in the year following hospitalization for stroke  
 
Panel B: Events per PY (admissions, DAOH) or per live discharge (discharge to home) 
 
Notes: PY=Person year. Incidence rate ratio estimates and 95% confidence intervals were generated using negative 
binomial models with log link and offset for log proportion of follow up days. Hazards ratios and 95% confidence 
intervals were generated using proportional hazards models. All models were adjusted for patient demographics, 
health status at discharge, medical history, hospital factors, county factors, no evaluation and management visit the 
year prior to incident stroke and fixed effects for Hospital Referral Region, and year/month of admission. 
 
Figure 11. Difference-in-difference estimates and 95% confidence intervals for MSSP versus 
non-MSSP Hospitals and estimates for the association of ACO-aligned beneficiaries with event 




Hospital Beneficiary Hospital Beneficiary Hospital Beneficiary




Hospital Beneficiary Hospital Beneficiary Hospital Beneficiary




* Value > 75
th
 vs ≤ 75
th
 percentile.  
Notes: ADI= Area Deprivation Index; PCP= Primary Care Physician; Care continuity (binary) is non-zero when 
the beneficiary is aligned with the same ACO providing acute stroke care during hospitalization. MSSP market 
penetration (continuous) is the proportion of hospital discharges where the beneficiary is aligned with any MSSP 
ACO. Area deprivation and PCP supply are county level factors from the Area Deprivation Index and Area Health 
Resource File respectively. 
  
Figure 12. Incidence Rate Ratios and 95% confidence intervals for rates of discharge to home 
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CHAPTER 5. MEDICARE SHARED SAVINGS ACOS AND PALLIATIVE CARE FOR 
STROKE PATIENTS: FINDINGS FROM GET WITH THE GUIDELINES-STROKE 
 5.1 Introduction 
Palliative care services, including use of the Medicare hospice benefit, have the potential 
to improve the quality of end-of-life (EOL) care at reduced cost, yet these services are underused 
among stroke patients.
9-12,23,146
 To improve quality of care and patient experience while 
controlling costs, accountable care organizations (ACOs) are expected to reduce use of low-
value and increase use of high-value services across the care continuum, including palliative 
care.
45-52
 Over half (60%) of ACOs have implemented EOL care planning processes, including 
care management and use management capabilities, however little is known about whether 
ACOs are changing use and quality of care at the EOL.
147
  
Palliative care, including care provided via the Medicare hospice benefit, is intended to 
be patient- and family-centered and optimize health-related quality of life by anticipating, 
preventing, and treating suffering, however these benefits are not fully realized for the 1 in 3 
hospice beneficiaries with a hospice stay of less than seven days.
35-41
 Although the vast majority 
of hospice care is provided in outpatient settings, most hospitals (50+ beds) offer inpatient 
palliative care or hospice services.
148
 For patients hospitalized close to the EOL, inpatient 
palliative care or comfort measures only (CMO) may be preferable to hospice services; EOL care 




Despite the expectation of increased use of palliative care services, Medicare ACO 





 This could reflect reductions in appropriate use of a high-value service; 
alternatively, the shift could be driven by changes in the tails such as fewer stays of longer than 
180 days. The latter could reduce hospice costs while maintaining or improving appropriate use 
of the hospice benefit. Proxies for potentially appropriate hospice use in ACOs such as 
enrollment among patients with limited life expectancy (LLE), timing of hospice enrollment 
relative to death, and live discharge rates remain largely unstudied.  
The objective of this study was to evaluate the association of the MSSP (hospital 
participation and beneficiary alignment) with quality of EOL care following incident ischemic 
stroke. Two specific hypothesis under this objective are: 1) MSSP will be associated with 
increased inpatient CMO and hospice use among patients with LLE, and 2) MSSP will be 
associated increased length of hospice use (e.g., median hospice days) among hospice users.  
5.2 Methods 
This study compares outcomes among two incident stroke populations: 1) patients 
presenting at a hospital participating in an MSSP ACO contract (referred to as MSSP hospital) or 
assigned to an MSSP ACO by Centers for Medicaid and Medicare Services (CMS) (referred to 
as ACO-aligned), and 2) stroke patients with neither MSSP exposure. To achieve this objective, 
we employed hospitalization data from the national Get with The Guidelines (GWTG)–Stroke 
registry linked to Medicare fee-for-service (FFS) inpatient and hospice claims files using an 
observational, difference-in-difference study design.  
Data Sources  
Hospitalization records from GWTG-Stroke registry for admissions from 2010 to 2013 
were linked to CMS denominator and inpatient claims files between 2010 and 2015 using a 
validated algorithm.
57
 The GWTG–Stroke registry provides a high quality data for a sample 
similar to the national Medicare stroke population. Quintiles is the data collection coordination 
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center for the American Heart Association/American Stroke Association Get With The 
Guidelines
®
 programs. The registry includes patient-level data on patient clinical risk factors, 
diagnostic testing results, and in-hospital outcomes as well as hospital characteristics including 
ownership, stroke center status, teaching hospital status, number of beds, rural status, and Census 
region.
58-60
 These data were merged with CMS MSSP provider and beneficiary-level files for 
performance year 2013 and the Area Heath Resource File (AHRF) for years 2010 to 2013 to 
obtain county-level socioeconomic characteristics. Duke University Institutional Review Board 
determined that the study did not involve human subjects and was thus exempt from review. 
Sample 
The sample included Medicare FFS patients hospitalized in a hospital participating in the 
GWTG–Stroke registry between January 2010 and December 2013 who were age 65 or older 
with a physician-adjudicated diagnosis of ischemic stroke and linked to CMS claims. Exclusion 
criteria include prior stroke or missing medical history (N=293,140) or patients hospitalized at 
sites missing more than 25% of registry data (N=12,113). Beneficiaries who linked to CMS FFS 
claims but were not FFS at the time of hospital discharge were excluded (N=24,124). Additional 
exclusions following linkage include discharge disposition as Left Against Medical Advice 
(n=838) or missing AHRF, race or discharge disposition (n=1,881), for a final sample of 
(N=256,682).  
Outcomes among beneficiaries meeting criteria for LLE are evaluated independently 
from the rest of the sample because the care trajectories are expected to vary between these two 
groups. Patients were identified as LLE if at least one of the following criteria was met: National 
Institutes of Health Stroke Scale (NIHSS) score ≥15, contraindication for evidence-based 








Separate ACO status measures for hospital participation and beneficiary alignment were 
obtained from the CMS MSSP provider and beneficiary-level files for 2013 and 2014. Two 
treatment groups were defined: 1) hospitals participating in an MSSP ACO contract and 2) ACO-
aligned beneficiaries. The difference-in-difference model included two key binary variables 
whose interaction identifies the effect of MSSP implementation: 1) MSSP Hospital, defined by 
discharge records as hospitals participating in an MSSP in any year during the study period, and 
2) post-MSSP, defined by discharge records as occurring after the date of the hospital’s MSSP 
contract initiation. The interaction of MSSP Hospital and Post-MSSP defined the differential 
change from pre-MSSP to post-MSSP participation relative to the concurrent change in the 
group with no MSSP participation conditional on year. 
ACO-aligned beneficiaries included all beneficiaries assigned to an MSSP ACO by CMS, 
including those hospitalized at non-MSSP hospitals. This binary indicator identified patients 
assigned to any MSSP ACO in the quarter prior to discharge using the preliminary quarterly 
assignment.
55
 Because stroke patients may not survive long enough following discharge to be 
assigned using the claims algorithm, ACO assignment was drawn from the period prior to 
hospitalization; this avoided selection bias for patients with short survival in the period directly 
following discharge.  
Outcomes 
 
Palliative care use included two binary measures: 1) a composite outcome including 
CMO or discharge to hospice during the index hospitalization and 2) hospice use within one 
year of discharge. Among hospice users, length of hospice use measures included: 1) 





 2) live discharge from hospice (binary), which has been used as a proxy for 
early enrollment; and 3) total number of days in hospice (continuous) in the two years 
following index hospitalization. 
Patient, Hospital, and County Characteristics 
Patient data provided by GWTG include age (five-year age categories), race (White, 
Black, Hispanic, Asian, and Other), gender, dual eligible status, medical history (current smoker, 
hypertension, diabetes, myocardial infarction, heart failure, and atrial fibrillation), stroke severity 
as measured by the NIHSS, and health status at discharge. Measures of health status included 
laboratory values (continuous), unable to ambulate on admission (binary), and degree of 
disability as measured by the Modified Rankin Scale at discharge (categorical). Chronic kidney 
disease was defined using estimated creatinine clearance (categorical).
70
 Hospital factors include 
number of beds (continuous), annual stroke volume (continuous), Census region (categorical), 
and binary indicators for rural status, teaching hospital, and primary stroke center. County-level 
factors obtained from the AHRF include continuous measures for proportion over age 65, 
number of hospice providers per 10,000 residents, number of primary care physicians per 10,000 
residents, number of hospice providers per 10,000 residents, proportion of households in poverty, 
and total population (log).  
Analyses  
Logistic regression was used to estimate the average differential effect of MSSP on the 
probability of binary outcomes (e.g., composite outcome, hospice use within one year, short stay, 
live discharge). Patients surviving less than seven days from the index hospital admission date 
were excluded from the model predicting short hospice stay because they were not eligible for 
the outcome. In addition to evaluating mean effects on hospice days using a linear model, 
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 percentiles for hospice days.  
Excluding observations with high levels of missing values for NIHSS and measures of 
health status could introduce substantial bias to the model. Thus, for patient covariates missing 
more than 1% of values, we used multiple imputation by fully conditional specification, a 
powerful and statistically valid method for creating imputations in large data sets.
71
 All analyses 
were conducted in SAS version 9.04.01.  
5.3 Results 
Palliative Care Use by LLE Group 
The analysis sample included index hospitalizations for 256,682 unique beneficiaries, of 
whom 52,090 met the criteria for LLE. Patient demographics and inpatient clinical measures 
were not substantially different between patients discharged from MSSP versus non MSSP 
hospitals (standardized difference <0.2) for either subgroup (Table 8). Hospitals participating in 
MSSP had substantially higher annual volumes of stroke admissions and were more likely to be 
teaching hospitals (standardized difference ≥0.2). MSSP hospitals were more likely to be located 
in counties with larger populations, lower poverty rates, and greater supply of primary care 
physicians than non-MSSP hospitals.  
Discharge from MSSP (versus non-MSSP hospital) was associated with a significant 
(p<.05) decrease in our composite outcome (inpatient CMO or discharge to hospice) for non-
LLE beneficiaries (Adjusted odds ratio (OR) = 0.78; 95% Confidence Interval (CI) = 0.69, 0.90). 
However, among patients with LLE, there was no significant association between MSSP status 
and the composite outcome (OR=1.06; CI=0.95, 1.19) (Figure 13). Among those with LLE, no 
there was no significant association between MSSP status and the composite outcome (OR=1.06; 
CI=0.95, 1.19) (Figure 13). Among LLE, beneficiary alignment with an ACO was associated 
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with a 17% increase in the odds of hospice enrollment in the year following stroke (OR= 1.17; 
CI= 1.03, 1.23), with a predicted probability from 19.3% among non-aligned and 21.4% among 
ACO-aligned beneficiaries (Figure 13). Among non-LLE, there was no significant change in 
hospice enrollment at one year by beneficiary-level ACO alignment (Table 9).  
Length of Use Among Hospice Users 
Among beneficiaries with any hospice use in the two years following stroke (N=72,115), 
41% had a short stay (<7 days) and 12% had a live discharge from hospice. The difference-in-
difference analysis found no significant change in either short stay or live discharge from hospice 
associated with discharge from MSSP hospital (Figure 14), however ACO-aligned beneficiaries 
have a 38.5% (CI=36.4%, 40.9%) predicted probability of a short stay compared to 41.3% 
(CI=40.9%, 41.6%) among non-aligned beneficiaries. 
The distribution of hospice days varied by LLE status. Among hospice users, the median 
length of use was 4 days (Interquartile range (IQR) = 2, 13) for beneficiaries with LLE compared 
to 11 days (IQR= 5, 39) for non-LLE (Figure 15). Quantile regression estimates for the shifts in 






 percentiles and 
95% CI are presented in Figure 16; see Tables 9 and 10 for detailed estimates. Hospital MSSP 
was significantly associated with an increase in the 25
th
 percentile of hospice days among 
beneficiaries with LLE (0.63 days, CI=0.33, 0.93) and reduction in median hospice days among 
beneficiaries without LLE (-1.20 days, CI= -2.38, -0.03) relative to the concurrent change at non-
MSSP hospitals in the respective LLE group. In contrast, ACO-alignment among beneficiaries 
with LLE was associated with a decrease of 1.13 (CI= -1.58, -0.69) at the 25
th
 percentile relative 
to non-aligned LLE beneficiaries. ACO-alignment among beneficiaries without LLE was 
associated with an increase in the 25
th
 percentile and median hospice days of 1.39 (CI=0.68, 




We evaluated the association of hospital participation in MSSP and beneficiary ACO-
alignment with improved quality of EOL care following incident ischemic stroke. Among 
beneficiaries with LLE, ACO-alignment was associated with a significant increase in hospice 
enrollment in the year following stroke, however among patients with low estimated mortality 
risk at discharge (non-LLE), hospitalization at MSSP hospital was associated with a reduction in 
the use of inpatient CMO or discharge to hospice. Among non-LLE beneficiaries who went on to 
enroll in hospice, beneficiary ACO-alignment was associated with an increase of nearly two days 
in hospice length of use. Our finding of contrasting effects in the subgroups of patients with and 
with LLE suggests that ACO incentives may encourage use of palliative care among those most 
likely to benefit, without promoting inappropriate early referral to hospice.  
The decrease in CMO and discharge to hospice among stroke patients with low mortality 
risk is consistent with studies that found reductions in hospice cost per capita among ACO-
aligned Medicare beneficiaries nationally.
4
 A study of a clinically vulnerable subgroup found no 
change in hospice spending associated with MSSP.
32
 In our cohort, any potential increase in 
hospice spending resulting from higher rates of hospice enrollment within one year of stroke 
among ACO-aligned LLE beneficiaries could be offset by reductions in enrollment rates for the 
rest of the cohort. Given the heterogeneity in effect by estimated mortality risk at discharge, 
studies evaluating end-of-life spending and outcomes could benefit from data sources providing 
measures of life expectancy not available in claims.  
Among non-LLE hospice users, ACO-aligned beneficiaries had a greater median length 
of use, which may reflect improved quality of EOL care. An increase of nearly two days in the 
median hospice number of days is particularly meaningful in this cohort, where the median 
length of use was only 5 and 11 days among LLE and non-LLE hospice users, respectively. A 
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previous study found that reporting they had enrolled too late had substantially fewer days in 
hospice compared to those who said that enrollment was too soon or at the right time (median: 
10 versus 24 days, respectively).
152
 The perception of being enrolled too late is associated with 
high unmet needs and reduced satisfaction with care.
150
 An increase in median hospice days was 
not observed among beneficiaries with LLE, potentially because survival following stroke is too 
brief for length of hospice use to be a modifiable outcome. 
Patients who are most likely to benefit from palliative care had an increase of 17% in the 
odds of hospice enrollment among beneficiaries with LLE, however the predicted probability of 
hospice use within one year of stroke among ACO-aligned beneficiaries was only 2 percentage 
points higher than among non-aligned beneficiaries (21% and 19%, respectively). Current 
Medicare ACO quality metrics are not specifically tied to care for patients who are seriously ill 
or require EOL care, which may limit the resources MSSP ACOs allocate to programs targeting 
these patients with advanced illness. MSSP contracts incentivize palliative care indirectly at best 
through the potential for shared savings resulting from reduced resource use in other care 
settings. In ACOs where the seriously ill represent a small proportion of the defined ACO 
population, there is little financial incentive to improve palliative and EOL care provided to this 
group.  
The small increase we found in hospice enrollment associated with the 2013 cohort of 
MSSP ACOs may be an early indication that the use of palliative care in Medicare ACOs will 
continue to grow over time. MSSP provided a pathway for gradually assuming risk for 
nascent ACO systems, and these systems may require years to fully implement care 
coordination strategies and effect change. In 2014, 76% of MSSP ACOs did not formally 
contract with a hospice or palliative care physician, and those that did were more likely to 
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have specialists (e.g., oncologists) in the network.
153
 Unlike Medicare Advantage contracts, 
MSSP contracts include hospice expenditures in calculations of per capita costs. As a result, 
increases in hospice spending could contribute to overall cost increases if there are not 
corresponding decreases in other types of spending. On the other hand, ACOs may share in 
the savings when hospice use reduces costs at the end of life, and the potential for Medicare 
cost savings is greater under the tiered hospice payment structure implemented in 2016.
154
  
Our findings should be interpreted in the context of several limitations. First, larger 
hospitals are more likely to participate in the GWTG–Stroke registry, so the generalizability to 
smaller, more rural institutions is limited.
58
 Second, patient ACO alignment is not randomized, 
and assignment may be correlated with differences between the treatment and control group that 
are not captured by the observable characteristics—for example, education level or 
socioeconomic status—however, models were adjusted for county-level socioeconomic factors 
to mitigate the potential for bias. Finally, although the importance of palliative care concurrent 
with curative care is recognized, claims indicators of palliative care consultation have low 
sensitivity, so the registry-reported use of inpatient CMO should improve reliability.
68,69
 
For patients with ischemic stroke, high-quality care includes advance care planning and 
family-centered care that recognizes the preferences of the patient and caregivers. Among 
ischemic stroke patients most likely to benefit from palliative care, MSSP was associated with 
increased hospice enrollment and inpatient comfort measures without increasing rates of live 
discharge from hospice. This balance between appropriate use in a targeted population and 
overuse of the benefit may be an early signal that MSSP contract incentives will motivate 




Table 8. Characteristics of GWTG–Stroke Medicare Beneficiaries With and Without Limited 
Life Expectancy by Hospital MSSP Participation (2010-2013) 
 
N= 163,065 N= 41,527 N= 41,406 N= 10,684 
Variable Mean SD Mean SD Mean SD Mean SD
Patient Characteristic
Age, median (25th-75th percentiles) 79 (72,85) 80 (73,86) 84 (77,89) 85 (78,90)
Demographic (%)
Female 56.4 57.3 66.4 67.8
Black 9.4 10.5 8.3 9.9
Hispanic 3.8 3.6 3.9 3.5
Asian 2.0 1.7 2.1 1.7
Medicaid 6.9 6.6 8.9 9.4
Private Insurance 36.3 41.4 34.5 38.2
Inpatient Clinical Measures
NIH Stroke Severity Score 4.0 (3.7) 4.0 (3.7) 20.2 (6.8) 20.2 (6.8)
GWTG Mortality Risk Score 3.5 (3.5) 3.5 (3.5) 18.1 (12.1) 18.2 (12.2)
Discharge to home, % 47.2 45.0 7.3 6.6
Unable to ambulate, % 12.8 13.5 63.7 65.1
CHA2DS2-VASc  2+, % 98.5 98.5 99.3 99.3
Chronic Kidney Disease, % 49.2 49.0 57.5 57.9
Body mass index 27.4 (6.6) 27.2 (6.3) 26.2 (6.8) 26.0 (6.3)
Diastolic blood 71.4 (12.3) 71.4 (12.2) 70.7 (13.5) 70.7 (13.6)
Systolic blood pressure 137.5 (21.1) 137.6 (21.0) 137.1 (23.3) 137.3 (23.2)
A1C measurement (0-20), % 6.4 (1.4) 6.4 (1.4) 6.2 (1.2) 6.2 (1.2)
High Density Lipoprotein (mg/dl) 45.1 (14.7) 45.8 (14.6) 45.4 (15.0) 46.0 (15.1)
Low Density Lipoprotein (mg/dl) 97.3 (37.8) 96.8 (37.4) 92.0 (36.4) 92.0 (36.2)
Heart Rate 78.8 (17.1) 78.8 (17.0) 84.1 (20.6) 84.1 (20.7)
International normalized ratio 1.2 (.5) 1.2 (.5) 1.2 (.6) 1.2 (.5)
Medical History (%)
Atrial Fibrillation 22.2 23.0 44.9 45.6
Carotid Stenosis 4.1 4.4 3.3 3.4
Diabetes 32.0 31.6 28.4 28.2
Peripheral Vascular disease 5.2 5.5 6.1 6.2
Hypertension 84.3 84.7 83.1 83.7
Smoking 10.8 10.5 6.4 6.4
Dyslipidemia 49.8 51.1 40.9 41.0
Heart Failure 9.8 10.0 18.3 18.8
Transient Ischemic Sroke 10.0 10.0 8.5 8.8
Family History of Stroke 2.1 2.4 1.3 1.6
Hospital Characteristics
Number of Beds 399.8 (271.5) 443.2 (283.2) 420.4 (289.2) 469.3 (297.8)
Annual Stroke Admissions 312.4 (201.4)^ 362.2 (245.1) 334.5 (211.9)^ 384.0 (256.1)
Rural, % 6.4 3.5 5.9 3.5
Teaching, % 53.2 ^ 66.6 56.9 ^ 70.6
Region (%)
Northeast 24.7 31.9 24.5 31.4
Midwest 20.4 25.3 20.6 24.0
South 38.4 32.0 37.7 33.4
West 16.5 10.8 17.2 11.1
County Characteristics
Total Population (log) 12.7 (1.5)^ 13.0 (1.5) 12.7 (1.6)^ 13.0 (1.5)
Proportion Age 65+ 0.14 (.04) 0.14 (.03) 0.15 (.04) 0.14 (.03)
Proportion Households in Poverty 0.15 (.05)^ 0.14 (.05) 0.15 (.05)^ 0.14 (.05)
# Primary care physicians (per 10,000) 7.7 (3.0)^ 8.3 (3.3) 7.6 (3.0) 8.3 (3.3)
Number of Hospice providers (per 10,000) 0.6 (.2) 0.5 (.1) 0.6 (.2) 0.5 (.1)
^ Absolute value of the standardized difference between MSSP and not MSSP > 0.2;
MSSP HospitalsNot MSSP Not MSSP MSSP Hospitals
Limited Life ExpectancyNot Limited Life Expectancy
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Panel A: Comfort measures only (CMO) during hospitalization or discharge to hospice 
 
Panel B. Hospice enrollment within 1 year of discharge 
 
Notes: LLE=Limited Life Expectancy at discharge (defined as meeting one of the following criteria: National 
Institutes of Health Stroke Scale (NIHSS) score of ≥15; provider reported limited life expectancy as contraindication 
for treatment in GWTG-Stroke reporting; GWTG-Stroke mortality risk prediction score > 0.15). Average Marginal 
Effects were estimated using recycled predictions from logistic models and bootstrapped confidence intervals over 
100 replications. All models are adjusted for patient demographics, stroke severity, health status at discharge, 
medical history, hospital factors, county factors, no evaluation and management visit the year prior to incident 
stroke, fixed effects for hospital referral regions and year/month of admission. 
 
Figure 13. Predicted probability of comfort care among patients with and without Limited Life 

















































































Figure 15. Distribution of days in hospice among LLE and not-LLE among hospice users. 
  







No MSSP Hospital MSSP ACO-Aligned
Beneficiary
No MSSP Hospital MSSP ACO-Aligned
Beneficiary
Stay <7 Days  (N=63,956) Live Discharge (N=72,115)
5% 25% 50% 75% 95%
LLE 1 2 5 13 73








































Table 9. Associations of Hospital MSSP Participation and Beneficiary MSSP Assignment with 
Hospice Use and Outcomes of Hospice Use Among Hospitalized Stroke Patients 
Among patients with index hospitalization 2010-2013 (N=256,682) 





DD for Hospital MSSP  
  LLE 1.06 (0.95,1.19) 
Not LLE 0.78 (0.69,0.90) 
Beneficiary MSSP 
  LLE 1.03 (0.90,1.17) 
Not LLE 0.97 (0.83,1.13) 





DD for Hospital MSSP 
  LLE 1.04 (0.93,1.16) 
Not LLE 1.02 (0.94,1.10) 
Beneficiary MSSP 
  LLE 1.17 (1.03,1.23) 
Not LLE 0.98 (0.89,1.08) 
Among patients hospitalized 2010-2013 with hospice use within 2 years of discharge 2010-
2015 (N=72,115) 





DD for Hospital MSSP 1.03 (0.94,1.14) 
Beneficiary MSSP 0.89 (0.79,1.01) 





DD for Hospital MSSP 0.93 (0.81,1.08) 





Table 10. Association of MSSP Status with Total Hospice Days in the 2 Years Following 
Hospitalization for Stroke 







MSSP Hospital -0.33 -1.31 0.65 0.50 
MSSP Hospital LLE 0.63 0.33 0.93 <.001 
AC0-Aligned 1.39 0.68 2.10 <.001 
ACO-Aligned LLE -1.13 -1.58 -0.69 <.001 
0.5 
MSSP Hospital -1.20 -2.38 -0.03 0.045 
MSSP Hospital LLE 0.19 -0.38 0.76 0.512 
AC0-Aligned 1.84 0.19 3.50 0.029 
ACO-Aligned LLE -0.19 -0.94 0.56 0.616 
0.75 
MSSP Hospital -1.97 -5.27 1.34 0.243 
MSSP Hospital LLE 1.49 -0.37 3.34 0.116 
AC0-Aligned 2.92 -1.74 7.58 0.219 
ACO-Aligned LLE -0.82 -2.71 1.08 0.398 
GLM 
 
   
 
Mean 
MSSP Hospital 0.38 -1.32 2.08 0.664 
MSSP Hospital LLE 0.97 -1.35 3.28 0.413 
AC0-Aligned 1.42 -0.62 3.47 0.172 
ACO-Aligned LLE -1.32 -4.16 1.52 0.362 
MSSP=Medicare Shared Savings Program; LLE= Limited Life Expectancy subgroup; 










CHAPTER 6. SUMMARY, IMPLICATIONS, AND CONCLUSIONS 
This research improves our understanding of the early impacts of the MSSP on acute care 
in the year following ischemic stroke. I expected to learn whether and how discharge from a 
hospital participating versus not participating in MSSP and beneficiary ACO alignment versus 
not were associated with outcomes following stroke. The combined results from all three aims 
suggest that MSSP is associated with higher intensity post–acute care and improved quality of 
end-of-life care among patients with stroke. The finding of increased use of SNF and IRF for 
beneficiaries discharged from MSSP hospitals and increased hospital admissions ACO-aligned 
beneficiaries is contrary to my hypothesis that MSSP would be associated with reduced acute 
care use. My findings are consistent with evidence that early ACO savings are not driven by 
reductions in use for complex, high-cost patient groups. This research provides insights for the 
effectiveness of the current MSSP incentives and raises the need for future research to better 
understand the role of MSSP in reducing fragmentation in post–acute stroke care as well as 
improving stroke outcomes. 
6.1 Summary of Findings 
My systematic review of the evidence for the effect of ACOs on care processes and 
outcomes is mixed, potentially due to the variability in contract incentives across payer programs 
and outcome measures. The incentives for efficiency within ACO contracts have not negatively 
impacted common care quality measures or patient satisfaction, however there is little evidence 
to support the hope that ACOs have fulfilled on their promise of improved care at reduced cost in 
the early years of implementation.  
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For both of my studies, I used an analytic dataset that linked the national GWTG–Stroke 
hospital registry data with Medicare claims files for one year outcomes, CMS MSSP beneficiary- 
and provider-level files for MSSP exposure, and the Area Health Resource File for local market 
factors. For all three aims, I employed a difference-in-difference method to evaluate the 
association of the MSSP with use, clinical outcomes, and quality of EOL care in patients with 
ischemic stroke. I used the GWTG data from the index hospitalization to differentiate a low 
mortality subgroup to evaluate long-term outcomes (study 1) and a high mortality, LLE subgroup 
to evaluate appropriate use of palliative and EOL care (study 2). 
Study 1 evaluated the association of MSSP with use and clinical outcomes in the year 
following incident stroke. The analysis sample was restricted to patients with relatively low 
mortality risk to ensure a survival period of sufficient duration to observe potential impact of 
improved care processes. I found that rather than shifting post-stroke care to lower intensity care 
settings, hospital participation in MSSP was associated with a 6% lower rate of discharge to 
home. Most patients not discharged to home were discharged to either SNF or IRF for post–acute 
care, so a reduction in discharge to home suggests higher intensity and higher cost of care 
following stroke. Relative to beneficiaries not assigned to MSSP, the adjusted risk of 
rehospitalization and rate of subsequent admissions in the year following stroke for patients 
assigned to an MSSP increased by 3% and 5%, respectively. Despite the differential increase in 
rate of admissions following stroke, I did not observe a correlating increase in the total number 
of inpatient days. 
Study 2 evaluated the association of hospital participation in MSSP and beneficiary ACO 
alignment with improved quality of EOL care following incident ischemic stroke. Among 
patients with low mortality risk (not LLE), hospitalization at MSSP hospital was associated with 
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reduced use of inpatient CMO or discharge to hospice. Among patients with low mortality risk, 
hospitalization at MSSP hospital was associated with a reduction in the use of inpatient CMO or 
discharge to hospice. For patients with low mortality who went on to enroll in hospice, the 
median length of use was nearly two days greater for ACO-aligned compared to non-aligned 
beneficiaries.  
6.2 Implications for Policy and Practice 
These results have multiple implications for practice and policy. First, current incentives 
in MSSP contracts may not be sufficient to generate changes in post-stroke outcomes or 
reductions in acute care use among stroke patients. Of the 33 MSSP quality measures in 2013–
2014, two relate to patients with ischemic vascular disease.
144
 However, fragmentation of care 
and medication non-adherence are not specific to stroke patients, and introduction of quality 
measures for specific diagnosis groups would further burden providers with quality reporting. 
Over the next few years, CMS is introducing MSSP quality measures to target patients with 
multiple chronic conditions, which includes many stroke patients. These new measures, 
including unplanned admissions and post-discharge medication reconciliation, may refocus 
ACOs on care for these high-cost groups. 
Second, for hospitalized patients, hospital MSSP participation and beneficiary ACO 
alignment impact different aspects of the care trajectory. Across both studies, hospital 
assignment was significantly associated with outcomes proximate to the hospitalization (e.g., 
discharge destination), and beneficiary assignment was significantly associated with one-year 
outcomes that may be more likely to be impacted by outpatient care. I was surprised to find that 
the estimates for hospital MSSP associations were not sensitive to the inclusion of the 
beneficiary MSSP, suggesting that the acute care pathway is largely independent of primary care. 
In addition, there was no evidence of a benefit for ACO patients receiving acute care at the same 
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ACO providing their primary care. There may be an opportunity for ACOs to improve outcomes 
by further integrating acute care and post–acute care partners into successful outpatient care 
delivery models like the Patient Centered Medical Home.  
Third, I found contrasting effects associated with MSSP in the subgroups of patients 
identified with high versus low mortality risk, specifically for use of comfort measures and 
hospice enrollment. As a result, ACOs may increase use of palliative care among those most 
likely to benefit without increasing hospice days or cost across the Medicare population. 
Although these effects were small in magnitude, the vast majority of ACOs in this study 
participated in Track 1 contracts, which include shared savings but no downside risk. MSSP 
impacts on quality and outcomes may be magnified as ACOs gain experience and transition to 
risk-bearing tracks of MSSP or Next Generation ACO contracts.  
6.3 Next Steps and Future Research 
Although these early results are valuable signals to predict the potential impact of MSSP 
on care and outcomes, the long-term impacts of the program may change as ACOs become more 
integrated and payer contracts evolve. This study evaluated acute care use and EOL care, but the 
impact of MSSP on cost, use of high-quality post–acute care facilities, and quality of life 
following stroke is unknown. As Medicare ACO contracts evolve, studying the impact of 
changes in assignment methodologies and risk adjustment will inform implementation of the 
ACO strategy. Finally, the potential for unintended impacts on existing health disparities should 
be considered as alternative payment models are defined and implemented.  
The observed increase in use of inpatient care following stroke may reflect greater use of 
IRF, which has been associated with improved patient outcomes, as opposed to less intensive 
care settings (e.g., skilled nursing facility or home health).
141
 In addition to controlling costs, 
ACOs are expected to be a vehicle for creating high-quality referral networks, increasing use of 
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providers with a pattern of high-value care. Little research has explored how referral patterns 
have been impacted by dissemination of the ACO model.
109
 Among patients with serious illness, 
the relationship between cost and quality is another source of uncertainty. As ACOs seek to 
improve care coordination in post-stroke care, the financial incentives for cost reduction could 
either promote or hinder improvements in quality of care depending on the implications of 
quality for CMS reimbursement.  
As Medicare ACOs transition to prospective assignment contracts, more decedents are 
likely to be included in the defined population used to evaluate ACO performance. The extent to 
which this change will impact health systems’ approach to population management is unknown. 
We defined beneficiary ACO alignment using claims prior to the period over which outcomes 
were assessed, which includes a patient population similar to a prospective assignment 
methodology. In a prospective assignment contract, beneficiaries who die during the ACO 
performance period are just as likely to be assigned as those who survive the performance period, 
however, in a retrospective claims-based assignment contract, decedents are less likely to be 
assigned than those who survive due to a reduction in the time over which they generate the FFS 
claims used in the assignment algorithm. If patients with advanced illness and approaching the 
end of life represent a larger portion of the population in prospective contracts, then ACOs may 
have greater motivation to target these high-risk groups with care management programs as CMS 
increases use of prospective assignment. 
Finally, future research should examine unintended impacts on disparities. Provider 
participation in ACOs is lower in poorer communities and safety net providers are less likely to 
generate savings in alternative payment models when they do participate.
155-157
 Furthermore, 
high-spending ACOs generate more savings than low-spending ACOs, potentially rewarding 
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systems starting with greater inefficiency.
158
 Contributing to these undesirable financial impacts, 
ACOs serving minorities lag on quality standards for savings eligibility.
159
  
Providers serving vulnerable populations often have fewer resources available to fund 
quality improvement programs and information technology. They may also face challenges in 
meeting the broad needs of their patient populations due to social determinants of health, 
particularly in rural areas with fewer community resources available to support the healthcare 
system and higher comorbidity burden. Hospitals participating in ACOs tend to be large and 
urban, and the unequal distribution of ACOs across rural and urban areas may widen the 
disparity between these groups as well.
160
 The Advance Payment Model has facilitated 
dispersion of the ACO model to smaller organizations with fewer resources, and policy makers 
should continue to explore additional strategies to both encourage participation and fairly 
compensate ACOs serving vulnerable populations. In addition, research should inform policies 
that will counteract the potential for the pay for performance aspects of ACO contracts to further 
shift resources away from deprived markets.  
6.4 Conclusion 
This study provides modest evidence that ACOs positively impact quality of EOL care 
among ischemic stroke patients with high mortality risk but failed to find evidence of improved 
clinical outcomes or reductions in acute care use. Given the rapid adoption of the ACO strategy 
nationally, it is essential that we understand the relationship between ACOs and stroke outcomes. 
Further studies are warranted to assess the downstream impacts of ACOs and other alternative 
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